NZ733006A - Rpe cell populations and methods of generating same - Google Patents
Rpe cell populations and methods of generating sameInfo
- Publication number
- NZ733006A NZ733006A NZ733006A NZ73300615A NZ733006A NZ 733006 A NZ733006 A NZ 733006A NZ 733006 A NZ733006 A NZ 733006A NZ 73300615 A NZ73300615 A NZ 73300615A NZ 733006 A NZ733006 A NZ 733006A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- rpe
- cell
- cell population
- medium
- Prior art date
Links
- 102100006820 PMEL Human genes 0.000 claims abstract description 77
- 101700035121 PMEL Proteins 0.000 claims abstract description 77
- 210000004027 cells Anatomy 0.000 claims description 750
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 98
- 230000028327 secretion Effects 0.000 claims description 96
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims description 80
- 102000003740 pigment epithelium-derived factor Human genes 0.000 claims description 80
- 235000005152 nicotinamide Nutrition 0.000 claims description 50
- 239000011570 nicotinamide Substances 0.000 claims description 50
- 229960003966 nicotinamide Drugs 0.000 claims description 50
- 210000001671 Embryonic Stem Cells Anatomy 0.000 claims description 47
- 102100015249 VEGFA Human genes 0.000 claims description 41
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 41
- 102100018024 ANG Human genes 0.000 claims description 35
- 108010072788 angiogenin Proteins 0.000 claims description 35
- 108010023082 activin A Proteins 0.000 claims description 32
- 102100006014 TIMP2 Human genes 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 150000002500 ions Chemical class 0.000 claims description 24
- 210000000130 stem cell Anatomy 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims description 20
- 230000001464 adherent Effects 0.000 claims description 20
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 20
- 241000700159 Rattus Species 0.000 claims description 19
- 101700065146 TIMP2 Proteins 0.000 claims description 19
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 19
- 210000002950 fibroblast Anatomy 0.000 claims description 17
- 238000010186 staining Methods 0.000 claims description 17
- 210000001519 tissues Anatomy 0.000 claims description 16
- 102000013810 Bestrophin-1 Human genes 0.000 claims description 15
- 108050003623 Bestrophin-1 Proteins 0.000 claims description 15
- 235000020945 retinal Nutrition 0.000 claims description 15
- 239000011604 retinal Substances 0.000 claims description 15
- 102100008634 FGF2 Human genes 0.000 claims description 13
- 101700082364 FGF2 Proteins 0.000 claims description 13
- 102000007354 PAX6 Transcription Factor Human genes 0.000 claims description 13
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 13
- 108010032788 PAX6 Transcription Factor Proteins 0.000 claims description 11
- 230000001413 cellular Effects 0.000 claims description 11
- 238000001711 protein immunostaining Methods 0.000 claims description 11
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 10
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 10
- 201000007737 retinal degeneration Diseases 0.000 claims description 10
- 230000004258 retinal degeneration Effects 0.000 claims description 9
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 8
- 108091008017 photoreceptors Proteins 0.000 claims description 8
- 210000001316 polygonal cell Anatomy 0.000 claims description 8
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 206010054094 Tumour necrosis Diseases 0.000 claims description 7
- 238000004115 adherent culture Methods 0.000 claims description 7
- 239000006285 cell suspension Substances 0.000 claims description 7
- 108010059616 Activins Proteins 0.000 claims description 6
- 102100008240 INHBE Human genes 0.000 claims description 6
- 239000000488 activin Substances 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 230000004304 visual acuity Effects 0.000 claims description 6
- 241000219430 Betula pendula Species 0.000 claims description 5
- 102000006240 membrane receptors Human genes 0.000 claims description 5
- 108020004084 membrane receptors Proteins 0.000 claims description 5
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 4
- NCYCYZXNIZJOKI-OVSJKPMPSA-N all-trans-retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 4
- 230000000644 propagated Effects 0.000 claims description 4
- 230000001902 propagating Effects 0.000 claims description 4
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-Aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 claims 2
- HOVQIIGVBKXWRZ-UHFFFAOYSA-N 2-amino-4-methoxy-3-pentoxybenzaldehyde Chemical compound CCCCCOC1=C(N)C(C=O)=CC=C1OC HOVQIIGVBKXWRZ-UHFFFAOYSA-N 0.000 claims 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 101710027855 GLRG_06511 Proteins 0.000 claims 1
- 102100014320 TGFB1 Human genes 0.000 claims 1
- 101700041213 TGFB1 Proteins 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 claims 1
- 108091007650 binding proteins Proteins 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 102100016410 RLBP1 Human genes 0.000 abstract description 87
- 101700054796 RLBP1 Proteins 0.000 abstract description 87
- 210000003583 Retinal Pigment Epithelium Anatomy 0.000 description 295
- 210000004544 DC2 Anatomy 0.000 description 66
- 230000004069 differentiation Effects 0.000 description 65
- 230000002530 ischemic preconditioning Effects 0.000 description 64
- 210000001508 Eye Anatomy 0.000 description 63
- 238000004519 manufacturing process Methods 0.000 description 53
- 239000002609 media Substances 0.000 description 50
- 238000000034 method Methods 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 29
- 229920001184 polypeptide Polymers 0.000 description 27
- 238000004166 bioassay Methods 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 24
- 102000004965 antibodies Human genes 0.000 description 21
- 108090001123 antibodies Proteins 0.000 description 21
- 239000003550 marker Substances 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 210000001525 Retina Anatomy 0.000 description 19
- 239000000825 pharmaceutical preparation Substances 0.000 description 19
- 238000002054 transplantation Methods 0.000 description 18
- 102100014646 MITF Human genes 0.000 description 17
- 230000012010 growth Effects 0.000 description 16
- 230000001225 therapeutic Effects 0.000 description 15
- 210000002966 Serum Anatomy 0.000 description 14
- 238000005138 cryopreservation Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 210000002459 Blastocyst Anatomy 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 210000004940 Nucleus Anatomy 0.000 description 12
- 101700033491 RPE65 Proteins 0.000 description 12
- 102100000549 RPE65 Human genes 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000002207 retinal Effects 0.000 description 12
- 230000004083 survival Effects 0.000 description 11
- 102100014858 AMH Human genes 0.000 description 10
- 210000003996 CFU-GM Anatomy 0.000 description 10
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 10
- 208000002780 Macular Degeneration Diseases 0.000 description 10
- 102000004330 Rhodopsin Human genes 0.000 description 10
- 108090000820 Rhodopsin Proteins 0.000 description 10
- 210000004127 Vitreous Body Anatomy 0.000 description 10
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 235000013928 guanylic acid Nutrition 0.000 description 10
- 239000012535 impurity Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 102100003929 LRAT Human genes 0.000 description 9
- 230000004888 barrier function Effects 0.000 description 9
- 230000001809 detectable Effects 0.000 description 9
- 230000001605 fetal Effects 0.000 description 9
- 108010084957 lecithin-retinol acyltransferase Proteins 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000001537 neural Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000010257 thawing Methods 0.000 description 9
- 206010064930 Age-related macular degeneration Diseases 0.000 description 8
- 102000012304 Bestrophin Human genes 0.000 description 8
- 108050002823 Bestrophin Proteins 0.000 description 8
- 210000002744 Extracellular Matrix Anatomy 0.000 description 8
- 102100003278 GDF3 Human genes 0.000 description 8
- 101700054531 GDF3 Proteins 0.000 description 8
- 108060004872 MIF Proteins 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 8
- 230000036512 infertility Effects 0.000 description 8
- 238000003908 quality control method Methods 0.000 description 8
- 231100000803 sterility Toxicity 0.000 description 8
- 101700030874 SOX9 Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- DHRJOYDLBMLIFJ-UHFFFAOYSA-N cresyl violet Chemical compound C1=CC=C2C3=NC4=CC=C(N)C=C4[O+]=C3C=C(N)C2=C1 DHRJOYDLBMLIFJ-UHFFFAOYSA-N 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000003498 protein array Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 210000004556 Brain Anatomy 0.000 description 6
- 210000000981 Epithelium Anatomy 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- -1 PF- 01367338) Chemical compound 0.000 description 6
- 208000007014 Retinitis Pigmentosa Diseases 0.000 description 6
- 210000000278 Spinal Cord Anatomy 0.000 description 6
- 102100002607 TIMP1 Human genes 0.000 description 6
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 6
- 239000003855 balanced salt solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 101710027066 ALB Proteins 0.000 description 5
- 230000037177 Biodistribution Effects 0.000 description 5
- 208000002352 Blister Diseases 0.000 description 5
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 102000007547 Laminin Human genes 0.000 description 5
- 108010085895 Laminin Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000038129 antigens Human genes 0.000 description 5
- 108091007172 antigens Proteins 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000002255 enzymatic Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 150000005480 nicotinamides Chemical class 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 201000011056 retinal disease Diseases 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 102100007149 BEST1 Human genes 0.000 description 4
- 101700047202 BEST1 Proteins 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 102000020504 Collagenase family Human genes 0.000 description 4
- 108060005980 Collagenase family Proteins 0.000 description 4
- 210000002216 Heart Anatomy 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 210000003734 Kidney Anatomy 0.000 description 4
- 239000012480 LAL reagent Substances 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 210000001165 Lymph Nodes Anatomy 0.000 description 4
- 210000002752 Melanocytes Anatomy 0.000 description 4
- 101700033949 RPE Proteins 0.000 description 4
- 102100017582 RPE Human genes 0.000 description 4
- 210000000952 Spleen Anatomy 0.000 description 4
- 210000001541 Thymus Gland Anatomy 0.000 description 4
- 230000001058 adult Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000006143 cell culture media Substances 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 230000002596 correlated Effects 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000056 organs Anatomy 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000002062 proliferating Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 4
- 102100001692 ARR3 Human genes 0.000 description 3
- 101700064490 ARR3 Proteins 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 210000002304 ESC Anatomy 0.000 description 3
- 102100019126 HBB Human genes 0.000 description 3
- 108091005902 Hemoglobin subunit beta Proteins 0.000 description 3
- 206010062080 Pigmentation disease Diseases 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 102100015788 SOX9 Human genes 0.000 description 3
- 210000003954 Umbilical Cord Anatomy 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960005188 collagen Drugs 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000003902 lesions Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000003442 weekly Effects 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
- 102100015886 BMP4 Human genes 0.000 description 2
- 101700005069 BMP4 Proteins 0.000 description 2
- 102100015880 BMP6 Human genes 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 229940112869 Bone morphogenetic proteins Drugs 0.000 description 2
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 2
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 2
- 102100007493 CNTF Human genes 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102000003712 Complement Factor B Human genes 0.000 description 2
- 108090000056 Complement Factor B Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010011906 Death Diseases 0.000 description 2
- 210000003981 Ectoderm Anatomy 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100008658 FN1 Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 101700085508 KCNH2 Proteins 0.000 description 2
- 101700011826 KCNH6 Proteins 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 210000002780 Melanosomes Anatomy 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 210000000933 Neural Crest Anatomy 0.000 description 2
- 210000001328 Optic Nerve Anatomy 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 101700083667 PAX6 Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 210000000964 Retinal Cone Photoreceptor Cells Anatomy 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 210000004927 Skin cells Anatomy 0.000 description 2
- 210000001550 Testis Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 210000002268 Wool Anatomy 0.000 description 2
- 210000004340 Zona Pellucida Anatomy 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000868 anti-mullerian hormone Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003636 conditioned culture media Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002257 embryonic structures Anatomy 0.000 description 2
- 210000002919 epithelial cells Anatomy 0.000 description 2
- 230000032686 female pregnancy Effects 0.000 description 2
- 230000037320 fibronectin Effects 0.000 description 2
- 230000007045 gastrulation Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002519 immonomodulatory Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000002577 ophthalmoscopy Methods 0.000 description 2
- 230000004380 optic nerve Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000270 postfertilization Effects 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 201000007714 retinoschisis Diseases 0.000 description 2
- 238000003530 single readout Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 230000002110 toxicologic Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 230000001228 trophic Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-Aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
- ZLWYEPMDOUQDBW-UHFFFAOYSA-N 6-aminonicotinamide Chemical compound NC(=O)C1=CC=C(N)N=C1 ZLWYEPMDOUQDBW-UHFFFAOYSA-N 0.000 description 1
- 102100011470 ABCA4 Human genes 0.000 description 1
- 102100008450 AFP Human genes 0.000 description 1
- 101700026109 AGRP Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 210000002718 Aborted Fetus Anatomy 0.000 description 1
- 102000019632 Acyl transferases Human genes 0.000 description 1
- 108091022082 Acyl transferases Proteins 0.000 description 1
- 210000004504 Adult Stem Cells Anatomy 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000037640 Animal pathogens Species 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 101710017228 BG04 Proteins 0.000 description 1
- 102100005377 BMP2 Human genes 0.000 description 1
- 101700000123 BMP2 Proteins 0.000 description 1
- 101700001588 BMP3 Proteins 0.000 description 1
- 102100005375 BMP3 Human genes 0.000 description 1
- 101700086945 BMP6 Proteins 0.000 description 1
- 102100015882 BMP7 Human genes 0.000 description 1
- 101700060441 BMP7 Proteins 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 210000004155 Blood-Retinal Barrier Anatomy 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100019487 CCL11 Human genes 0.000 description 1
- 101700074178 CCL11 Proteins 0.000 description 1
- 102100019485 CCL13 Human genes 0.000 description 1
- 101700034979 CCL13 Proteins 0.000 description 1
- 102100019494 CCL17 Human genes 0.000 description 1
- 101700084100 CCL17 Proteins 0.000 description 1
- 102100016449 CCL5 Human genes 0.000 description 1
- 102100016450 CCL7 Human genes 0.000 description 1
- 101700044004 CCL7 Proteins 0.000 description 1
- 102100016451 CCL8 Human genes 0.000 description 1
- 101700045693 CCL8 Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100009637 CXCL11 Human genes 0.000 description 1
- 101710032182 CXCL11 Proteins 0.000 description 1
- 102100009685 CXCL6 Human genes 0.000 description 1
- 101700033050 CXCL6 Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000004671 Cell-Free System Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 210000003161 Choroid Anatomy 0.000 description 1
- 206010008785 Choroidal dystrophy Diseases 0.000 description 1
- 208000003571 Choroideremia Diseases 0.000 description 1
- 210000004240 Ciliary Body Anatomy 0.000 description 1
- 210000000795 Conjunctiva Anatomy 0.000 description 1
- 210000004087 Cornea Anatomy 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 1
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 210000001900 Endoderm Anatomy 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102100007407 FGF6 Human genes 0.000 description 1
- 101700012851 FGF6 Proteins 0.000 description 1
- 102100007405 FGF7 Human genes 0.000 description 1
- 101700033323 FGF7 Proteins 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 210000003953 Foreskin Anatomy 0.000 description 1
- 101700048391 GCP2 Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 210000001654 Germ Layers Anatomy 0.000 description 1
- 102000004329 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108090000821 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000007698 Gyrate Atrophy Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 210000001822 Immobilized Cells Anatomy 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N Iniparib Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- 229950002133 Iniparib Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102000004375 Insulin-Like Growth Factor Binding Protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-Like Growth Factor Binding Protein 1 Proteins 0.000 description 1
- 102000004369 Insulin-Like Growth Factor Binding Protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-Like Growth Factor Binding Protein 4 Proteins 0.000 description 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 101700078593 LHX2 Proteins 0.000 description 1
- 102100004907 LHX2 Human genes 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N LSD Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 229950002454 Lysergide Drugs 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N MCP 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- 108010008148 Member 4 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 210000003716 Mesoderm Anatomy 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 208000009795 Microphthalmos Diseases 0.000 description 1
- 210000004253 Multipotent Stem Cells Anatomy 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- JMUPMJGUKXYCMF-UHFFFAOYSA-N N-[2-[2-[[6-[5-acetamido-6-(5-acetamido-1,2,4-trihydroxy-6-oxohexan-3-yl)oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-[3-[3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymet Chemical compound OC1C(NC(C)=O)C(OC(C(O)C(C=O)NC(=O)C)C(O)CO)OC(CO)C1OC1C(O)C(OC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)NC(C)=O)C(O)C(COC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)NC(C)=O)O1 JMUPMJGUKXYCMF-UHFFFAOYSA-N 0.000 description 1
- 101710042084 NAP1L4 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108010008267 Nerve Growth Factors Proteins 0.000 description 1
- 229940053487 Niacinamide Drugs 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229940116542 OTHER NUTRIENTS in ATC Drugs 0.000 description 1
- 102100006821 OTX2 Human genes 0.000 description 1
- 101700070147 OTX2 Proteins 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N Olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 101710043203 P23p89 Proteins 0.000 description 1
- 102100009687 PPBP Human genes 0.000 description 1
- 101710030036 PPBP Proteins 0.000 description 1
- 210000002741 Palatine Tonsil Anatomy 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108060002038 Pde4 Proteins 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 210000000608 Photoreceptor Cells Anatomy 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 210000000880 Retinal Rod Photoreceptor Cells Anatomy 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 101700041920 SIX3 Proteins 0.000 description 1
- 102100015678 SIX3 Human genes 0.000 description 1
- 101700049354 SIX6 Proteins 0.000 description 1
- 102100016001 SIX6 Human genes 0.000 description 1
- 210000003786 Sclera Anatomy 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- 206010062766 Stargardt's disease Diseases 0.000 description 1
- 210000001562 Sternum Anatomy 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102100016771 TGFBI Human genes 0.000 description 1
- 102100006015 TIMP3 Human genes 0.000 description 1
- 101710022243 TNFSF18 Proteins 0.000 description 1
- 101700019351 TRYM Proteins 0.000 description 1
- 101710037010 TUBGCP2 Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical class NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 1
- 210000001578 Tight Junctions Anatomy 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241001459538 Ute Species 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- 102100015205 VEGFD Human genes 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229950011257 Veliparib Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002491 angiogenic Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic Effects 0.000 description 1
- 230000003127 anti-melanomic Effects 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 108010068396 betaIG-H3 protein Proteins 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- XGRYDJSRYGHYOO-KJYQHMRQSA-N bis[[(1R,8R)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl] 2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate Chemical compound C1=CC(O)=CC=C1C1C(C(=O)OC[C@H]2[C@H]3CCCN3CC2)C(C=2C=CC(O)=CC=2)C1C(=O)OC[C@H]1[C@H]2CCCN2CC1 XGRYDJSRYGHYOO-KJYQHMRQSA-N 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 210000004271 bone marrow stromal cells Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108091004535 flt3 ligand protein Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940020899 hematological Enzymes Drugs 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large scale production Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- PXUQTDZNOHRWLI-OXUVVOBNSA-O malvidin 3-O-β-D-glucoside Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 PXUQTDZNOHRWLI-OXUVVOBNSA-O 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000002906 microbiologic Effects 0.000 description 1
- 201000010478 microphthalmia Diseases 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000001617 migratory Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000002276 neurotropic Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 230000000242 pagocytic Effects 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001023 pro-angiogenic Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000009201 retinal pigment epithelium development Effects 0.000 description 1
- 210000001164 retinal progenitor cell Anatomy 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000000143 trophectoderm cell Anatomy 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000000381 tumorigenic Effects 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Abstract
population of human polygonal RPE cells is disclosed. At least 95 % of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed. me are also disclosed.
Description
/051269
RPE CELL POPULATIONS AND METHODS OF GENERATING SAME
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to retinal pigment
epithelium cells and, more particularly, but not exclusively, to assessment of such cells
as a eutic. The present invention also relates to generation of l pigment
lium cells from embryonic stem cells.
The retinal pigment epithelium (RPE) is a monolayer of pigmented cells, which
lies between the neural retina and the choriocapillaris. The RPE cells play l roles
in the maintenance and function of the retina and its photoreceptors. These e the
ion of the blood—retinal barrier, absorption of stray light, supply of nutrients to
the neural retina, regeneration of Visual pigment, and uptake and recycling of shed outer
segments of eceptors.
Retinal tissue may degenerate for a number of reasons. Among them are: artery
or vein occlusion, diabetic retinopathy and retinopathy of prematurity, which are usually
hereditary. Diseases such as retinitis pigmentosa, retinoschisis, lattice degeneration,
Best disease, and age related r degeneration (AMD) are characterized by
progressive types of retinal degeneration.
RPE cells may potentially be used for cell replacement therapy of the
degenerating RPE in retinal diseases mentioned above. It may be also used as a vehicle
for the introduction of genes for the treatment of retinal degeneration diseases. These
cells may also serve as an in vitro model of retinal degeneration diseases, as a tool for
high throughput screening for a therapeutic effect of small molecules, and for the
discovery and testing of new drugs for retinal degeneration diseases. RPE cells could
also be used for basic ch of RPE development, maturation, characteristics,
ties, metabolism, immunogenicity, function and interaction with other cell types.
Human fetal and adult RPE has been used as an alternative donor source for
allogeneic transplantation. However, practical problems in obtaining sufficient tissue
supply and the ethical concerns regarding the use of tissues from aborted fetuses limit
widespread use of these donor s. Given these limitations in supply of adult and
fetal RPE grafts, the potential of alternative donor sources have been studied. Human
2015/051269
pluripotent stem cells provide significant advantages as a source of RPE cells for
transplantation. Their pluripotent developmental potential may enable their
differentiation into authentic functional RPE cells, and given their potential for infinite
self l, they may serve as an unlimited donor source of RPE cells. Indeed, it has
been demonstrated that human embryonic stem cells (hESCs) and human d
pluripotent stem cells (iPS) differentiate into RPE cells in vitro, attenuate retinal
ration and preserve visual function after subretinal transplantation to the Royal
College of ns (RCS) rat model of l degeneration that is caused by RPE
dysfunction. Therefore, otent stem cells may be an unlimited source for the
production of RPE cells.
Current protocols for the derivation of RPE cells from pluripotent stem cells
yields mixed populations of pigmented and non—pigmented cells. However, pure
populations of pigmented cells are d for the usage of RPE cells in basic research,
drug discovery and cell therapy.
ound art includes WO 2013/114360, WO 2008/129554 and WO
2013/184809.
SUMMARY OF THE INVENTION
According to an aspect of some embodiments of the present invention there is
provided a population of human polygonal RPE cells, wherein at least 95 % of the cells
thereof co—express premelanosome protein (PMEL17) and cellular retinaldehyde
binding protein (CRALBP), wherein the trans—epithelial electrical resistance of the
population of cells is greater than 100 ohms.
ing to an aspect of some embodiments of the present invention there is
provided a population of human RPE cells, wherein at least 80 % of the cells thereof co—
express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein
(CRALBP) and wherein cells of the population secrete each of angiogenin, tissue
inhibitor of metalloproteinase 2 (TIMP 2), soluble glycoprotein 130 (sgpl30) and
soluble form of the ubiquitous ne receptor 1 for tumor necrosis factor-0t (sTNF—
R1).
According to ments of the invention, the cells of the population secrete
each of angiogenin, tissue inhibitor of metalloproteinase 2 (TIMP 2), soluble
glycoprotein 130 (sgp130) and soluble form of the ubiquitous membrane receptor 1 for
tumor necrosis factor—0c (sTNF—Rl).
According to embodiments of the invention, the cells secrete the angiogenin, the
TIMPZ, the sgpl30 or the sTNF—Rl in a polarized manner.
According to embodiments of the invention, the cells secrete each of the
angiogenin, the TIMPZ, the sgpl30 and the sTNF—Rl in a zed manner.
According to embodiments of the invention, the ratio of apical secretion of
sgpl30: basal secretion of sgp130 is greater than 1.
According to embodiments of the invention, the ratio of apical secretion of
sTNF—Rl: basal ion of sTNF—Rl is greater than 1.
According to embodiments of the invention, the ratio of basal secretion of
angiogenin: apical secretion of angiogenin is r than 1.
According to ments of the invention, the ratio of apical secretion of
TIMP2: basal secretion of TIMP2 is r than 1.
According to embodiments of the invention, the number of Oct4‘LTRA—l—60+
cells in the population is below l:250,000.
According to ments of the invention, at least 80 % of the cells express
Bestrophin l, as measured by staining.
According to embodiments of the invention, at least 80 % of the cells express
Microphthalmia—associated ription factor {MITF), as measured by
staining.
According to embodiments of the invention, more than 50 % of the cells express
paired box gene 6 (FAX-6) as ed by FACS.
According to embodiments of the invention, the cells secrete greater than 750 ng
of Pigment epithelium—derived factor (PEDF) per ml per day.
According to embodiments of the invention, the cells secrete PEDF and vascular
endothelial growth factor (VEGF) in a polarized manner.
According to embodiments of the invention, the ratio of apical secretion of
PEDF: basal secretion of PEDF is greater than 1.
ing to embodiments of the invention, the ratio remains r than 1
following incubation for 8 hours at 2—8 0 C.
According to embodiments of the invention, the trans-epithelial electrical
resistance of the population of cells is greater than 100 ohms.
According to embodiments of the invention, the trans—epithelial electrical
resistance of the cells remains greater than 100 ohms following incubation for 8 hours at
2—8 0 C.
According to embodiments of the invention, the ratio of basal secretion of
VEGF: apical secretion of VEGF is greater than 1.
According to embodiments of the invention, the ratio remains greater than 1
following tion for 8 hours at 2—8 0 C.
According to embodiments of the invention, the cell population is capable of
rescuing visual acuity in the RC8 rat following subretinal administration.
According to embodiments of the invention, the cell population is capable of
rescuing photoreceptors for at least 180 days ubretinal administration in the RC8
rat.
According to embodiments of the invention, the cell population is ted by
ex—vivo differentiation of human embryonic stem cells.
According to embodiments of the invention, the cell population is generated by:
(a) culturing human embryonic stem cells in a medium comprising
nicotinamide so as to generate differentiating cells, wherein the medium is devoid of
activin A;
(b) culturing the differentiating cells in a medium comprising namide
and activin A to generate cells which are r differentiated towards the RPE lineage;
(c) culturing the cells which are r differentiated towards the RPE
e in a medium comprising nicotinamide, wherein the medium is devoid of activin
According to embodiments of the invention, the embryonic stem cells are
propagated in a medium comprising bFGF and TGFB.
According to embodiments of the ion, the embryonic stem cells are
cultured on human cord fibroblasts.
According to embodiments of the invention, the steps (a)-(c) are effected under
conditions wherein the atmospheric oxygen level is less than about 10 %.
According to embodiments of the invention, the method further ses
ing the differentiated cells in a medium under conditions wherein the atmospheric
oxygen level is greater than about 10 % in the presence of nicotinamide ing step
(c).
According to an aspect of some embodiments of the present invention there is
provided a pharmaceutical composition comprising the cell population described ,
as the active agent and a pharmaceutically acceptable carrier.
According to an aspect of some ments of the present invention there is
provided a use of the cell population described herein, for treating a retinal degeneration.
According to an aspect of some embodiments of the present invention there is
provided a method of generating RPE cells comprising:
(a) culturing pluripotent stem cells in a medium comprising a differentiating
agent so as to generate entiating cells, wherein the medium is devoid of a member
of the transforming growth factor B (TGF [3) superfamily;
(b) ing the differentiating cells in a medium comprising the member of
the transforming growth factor [3 (TGF [3) superfamily and the differentiating agent to
te cells which are further differentiated towards the RPE lineage;
(c) culturing the cells which are further differentiated towards the RPE
lineage in a medium comprising a differentiating agent so as to generate RPE cells,
wherein the medium is devoid of a member of the orming growth factor B (TGF [3)
superfamily, wherein steps (a)-(c) are effected under conditions wherein the
atmospheric oxygen level is less than about 10 %.
According to embodiments of the invention, step (a) is effected under non—
adherent conditions.
According to embodiments of the ion, the non-adherent conditions
comprise a non—adherent culture plate.
ing to embodiments of the invention, the step (a) comprises:
i) culturing the cultured population of human pluripotent stem cells in a
medium comprising nicotinamide, in the absence of activin A; under non—adherent
ions to generate a cluster of cells comprising differentiating cells; and
subsequently;
ii) culturing the differentiating cells of (i) in a medium sing
nicotinamide, in the absence of activin A under adherent conditions.
According to embodiments of the invention, the method. r comprises
dissociating the cluster of cells prior to step (ii) to generate clumps of cells or a single
cell suspension of cells.
According to embodiments of the invention, the method further comprises
culturing the differentiated cells in a medium under conditions wherein the heric
oxygen level is greater than about 10 % in the presence of a differentiating agent
following step (c).
According to embodiments of the invention, the member of the transforming
growth factor B (TGF [3) superfamily is selected from the group consisting of TGFBl,
TGFB3 and n A.
According to embodiments of the invention, the differentiating agent of step (a)
and the differentiating agent of step (c) are identical.
According to embodiments of the invention, the differentiating agent of step (a)
is nicotinamide (NA) or 3-- aminobenzamide.
According to embodiments of the invention, the method further comprises
selecting polygonal cells following step (c).
According to ments of the invention, the method further comprises
propagating the polygonal cells.
According to embodiments of the invention, the propagating is effected on an
adherent e or an extracellular matrix.
According to embodiments of the invention, the pluripotent stem cells comprise
embryonic stem cell 3
According to embodiments of the invention, the embryonic stem cells are
propagated in, a medium eomprising bFGF and TGFB.
According to ments of the invention, the embryonic stem cells are
cultured on human cord fibroblasts.
Unless otherwise defined, all technical and/or scientific terms used herein have
the same g as commonly understood by one of ordinary skill in the art to which
the invention pertains. Although methods and materials similar or equivalent to those
described herein can be used in the practice or testing of embodiments of the invention,
exemplary methods and/or materials are described below. In case of conflict, the patent
specification, including definitions, will control. In addition, the materials, methods, and
examples are illustrative only and are not intended to be necessarily limiting.
BRIEF DESCRIPTION OF THE L VIEWS OF THE GS
Some embodiments of the invention are herein bed, by way of example
only, with reference to the accompanying drawings. With specific reference now to the
drawings in detail, it is stressed that the particulars shown are by way of example and
for purposes of illustrative sion of embodiments of the invention. In this regard,
the description taken with the drawings makes apparent to those skilled in the art how
embodiments of the ion may be practiced.
In the drawings:
is a graph illustrating the linearity of the data.
is FACS analysis of negative control hESC cells stained with anti
CRALBP and anti PMEL 17.
is FACS analysis of positive control of the nce RPE line
OpRegen® 5C cells stained with anti CRALBP and anti PMEL 17.
is FACS analysis of 2.5% Spiked OpRegen® SC in hESCs d with
anti CRALBP and anti PMEL 17.
is FACS analysis of 50% Spiked OpRegen® SC in hESCs stained with
anti CRALBP and anti PMELI7.
is FACS is of 75% Spiked OpRegen® SC in hESCs stained with
anti CRALBP and anti PMELi7.
is FACS is of 95% Spiked OpRegen® SC in hESCs stained with
anti CRALBP and anti PMEL 17.
is FACS analysis of hESCs stained with Isotype Controls.
is FACS analysis of OpRegen® 5C cells stained with the Isotype
Controls.
: Co—immunostaining with PMEL17 differentiate RPE cells
(CRALBP+PMEL17+) from non RPE pigmented cells (PMEL17+ CRALBP—; such as
cytes).
: Morphology results for Mock 4 and 5 at In Process Control (H’C)
points 5, and 8—10.
: Manufacturing Process, Steps 1—3: Generation of Human Cord
Fibroblast Feeder Working Cell Bank.
: Manufacturing Process, Steps 4—5: Expansion of hESCs.
: Manufacturing Process, Steps 6—13: Differentiation into RPE
(OpRegen®) cells.
: Manufacturing Process, Steps 14—17: Expansion of pigmented cells.
: Detailed OpRegen® manufacturing process and in process control
points (yellow stars, lPCs 1—11). (NUTSPlus, Nutristem medium containing bFGF and
TGFB; nus, Nutristem medium w/o bFGF and TGFB; NIC, Nicotinamide; SB s,
Spheroid bodies).
: Level of CRALBP+PMEL17+ RPE cells along OpRegen® Mock
production runs 4 and 5. Density plots of IPC points 8 and 11 (*IPC point 8 was tested
post eservation) and representative density plots of positive l OpRegen®
5C and ve control HAD—C102 hESCs (range of % CRALBP+PMEL17+ in
negative control was 0.02—0.17%). Numbers within each plot indicate t
CRALBP+PMEL17+ cells out of the live single cell gated population. Analysis was
done using the FCS express 4 software.
: fluorescence staining of Mock 5 IPC points 7, 10 and 11 with
antibodies specific for the RPE s Bestrophin 1, MITF, 20—1 and CRALBP.
FIGs. 19A—C: Representative color fundus photograph of group 2 (BSS+; Figure
19A), group 5 contra lateral untreated eyes (OD; Figure 19B) and group 5 treated eyes
(OS; Figure 19C) at P60. The hyper and hypo-pigmented areas in the high dose treated
eyes (OS) are presumed to be indicative of transplanted cells.
: Optokinetic tracking acuity thresholds measured at P60, P100, P150,
and P200. Cell treated groups (group 3—25,000, group 4—100,000 and group 5—200,000)
outperformed all controls with the group 4 (100,000) and 5 (200,000) dose achieving
the best rescue. Contralateral unoperated eyes were equivalent to group 1 (untreated)
and group 2 (vehicle control/BSS+) (not shown).
FIGs. 21A-B: Graphs illustrating the Focal (Figure 21A) and Full field (Figure
21B) s for a representative rat.
FIGs. 22A—B: Figure 22A illustrates a photomontage of individual images of
cresyl violet d sections of a representative cell treated eye. Between the arrows
illustrates the location of photoreceptor tion and presumed location of the d
cells. Figure 22B illustrates the comparison between BSS+ (Group 2) injected eyes and
representative cell injected eyes (multiple dosage groups represented) at post—natal day
60, 100, 150 and 200. GCL: Ganglion Cell Layer; ONL: Outer Nuclear Layer; RPE:
Retinal Pigmented Epithelium.
: Outer r layer thickness measured in number of nuclei. Each dot
represents the count from each animal from every dose group for all ages.
: Immunofluorescent images of positive control tissue and representative
experimental cell treated animals at P60, P100, P150, and P200 stained with anti—human
nuclei marker (H.N.M, green), anti-pre—melanosomal marker (PMEL17, red), anti-
human proliferation marker (Ki67, red), and anti—rat cone arrestin (red). Dapi (blue) is
used for background staining to highlight nuclear layers. Human ma was used as
positive control tissue for PMELl7, human tonsil for Ki67, and juvenile RCS rat retina
for cone arrestin. Downward arrows te outer nuclear layer; upward arrows
indicate vely stained human RPE cells en®), generated as described herein.
is a graph illustrating cone quantification following inal
transplantation of OpRegen® cells into the RC8 rat. Cell d eyes were significantly
higher than control eyes at all ages.
FIGS. 26A—J: Immunofluorescent staining of OpRegen® cells in the subretinal
space. Figure 26A represents an area of retina with a number of RPE cells (red, arrows)
central and no debris zone (viewed using anti-rat rhodopsin antibody, green; arrow), but
where the cells are not (peripheral), the debris zone reconstitutes. At higher
magnification (Figure 26B), some rhodopsin stained outer segments rest along the
grafted cells. In addition, the debris zone reconstitutes as distance from transplanted
cells increases. Figures 26C—J are individual slices through the section showing
rhodopsin positive tissue within the transplanted cells (arrows).
FIGS. 27A—C are photographs illustrating the tribution of the cells
following subretinal injection into NOD—SCID. Figure 27A illustrates the ability of
OpRegen® cells to engraft in the ID subretinal space 9 months post transplant.
Pigmented cells stain positive for Human Nuclei and . Figure 27B is a
photograph illustrating the clustered cells at the place of the bleb following injection.
Figure 27C is a photograph illustrating the subsequent spreading of the cells into a
yer following injection.
is a pictorial illustration of a transwell assay that may be used to assay
the potency of RPE cells.
is the results of the FACS analysis illustrating PAX6 expression in RPE
cells generated as described herein (P2—DP, drug product: Mock IV, Mock V,
OpRegen® batch 2A; HuRPE: normal human RPE from ScienCell) and along
production (P0).
is a graph illustrating PAX6 expression in OpRegen® cells, as assayed
by FACS (HES, human embryonic stem cells used as negative control).
is the results of the FACS analysis rating double staining of PAX6
and .
FIGs. 32A—C are graphs illustrating ELISA assessment of Angiogenin secretion
by OpRegen® cells. A. Increased secretion of angiogenin along Mock V production. B.
Secretion of angiogenin by three different batches of n® cells (Passage 3) and
on a transwell for 3 weeks (Passage 4) during which apical and basal ion was
assessed. C. ion of angiogenin by RPE 7 cells (Passage 3).
FIGs. 33A—E illustrate TIMP—1 and TIMP—2 Secretion by OpRegen® cells. A.
ve TIMP—1 and TIMP—2 protein levels detected by protein array. B. ELISA TIMP—
2 levels in Mock V production QC points 3 and 4. C—D. ELISA TIMP—2 secretion levels
by different batches of OpRegen® cells (Passage 3) and on a ell for 3 weeks
during which apical and basal secretion was assessed (Passage 4). E. TIMP-2 levels
secreted from RPE 7 and HuRPE control cells (Passage 3, Days 4 & 14).
FIGS. 34A—D illustrate sgpl30 Secretion by OpRegen® Cells as measured by
ELISA. A. sgpl30 secretion levels in Mock V production QC points 3 and 4. B—C.
Levels of secreted sgpl30 by various batches of OpRegen® cells (Passage 3) and on a
transwell for 3 weeks during which apical and basal secretion was assessed (Passage 4).
D. sgp130 levels secreted from RPE 7 and HuRPE control cells (Passage 3, Days 4 &
14).
FIGS. 35A-D rate sTNF-Rl protein levels in OpRegen® cell supernatant as
measured by ELISA. A. sTNF—Rl levels in cell supernatant from Mock V tion
QC points 3 and 4. B—C. Levels of sTNF—Rl in the supernatant of OpRegen® s
(Passage 3) and on a transwell for 3 weeks during which apical and basal levels were
assessed (Passage 4). D. sTNF—Rl levels in day 4 and day 14 RPE7 and control HuRPE
cell cultures (Passage 3).
illustrates the morphology of OpRegen® 5C (Reference Line), RPEl
and RPE7 on Transwell. OpRegen® 5C, RPEl and RPE7 were imaged weekly (week 1—
4) following their seeding on transwell. OpRegen® 5C generated a homogeneous
polygonal monolayer from week 1 while RPEl and RPE7 generated a different non—
homogeneous logy one week post seeding and holes started to appear at week 2.
RPEl cells detached from the transwell after 3 weeks in culture.
illustrates that RPEl and RPE7 cells co—express CRALBP and PMEL—
17. FACS Purity assay demonstrated that 99.91% and 96.29% of RPEl and RPE7 cells,
respectively, are double positive for the RPE markers CRALBP and PMEL—l7, similar
to the levels seen in OpRegen® Mock V cells (Positive Control). HAD—C 102 hESCs
were used as the negative l.
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE ION
The present invention, in some ments thereof, relates to retinal t
epithelium cells and, more particularly, but not exclusively, to assessment of such cells
as a therapeutic. The present invention also relates to generation of retinal pigment
epithelium cells from human embryonic stem cells.
Before ning at least one embodiment of the invention in detail, it is to be
understood that the invention is not necessarily limited in its application to the details
set forth in the following description or exemplified by the Examples. The invention is
capable of other embodiments or of being practiced or carried out in various ways.
The neural retina initiates vision and is supported by the underlying retinal
pigment epithelium (RPE). Dysfunction, ration, and loss of RPE cells are
ent features of Best disease, subtypes of retinitis pigmentosa (RP), and age—
related macular degeneration (AMD), which is the leading cause of Visual disability in
the western world. In these conditions, there is progressive visual loss that often leads to
blindness.
The retina and adjacent RPE both arise from neural ectoderm. In lower s,
RPE rates retina but in mammals, RPE—mediated regeneration is inhibited and
renewal occurs to a very limited extent via stem cells located at the eral retinal
Human embryonic stem cells (hESC) may serve as an unlimited donor source of
RPE cells for transplantation. The potential of mouse, e, and human ESCS to
differentiate into RPE—like cells, to attenuate retinal degeneration, and to preserve visual
function after subretinal transplantation has been demonstrated.
Various protocols for the differentiation of human embryonic stem cells into
RPE cells have been developed (see for example WC 2008/129554).
The present inventors have now discovered a unique and simple way of
qualifying cell populations which have been successfully differentiated into RPE cells
based on expression of particular polypeptides. Of the myriad of ial polypeptides
expressed on these differentiated cells, the present inventors have found that a
combination of two particular markers can be used to ntiate successful
entiation.
The present inventors have also discovered that secretion of Pigment epithelium—
derived factor (PEDF) may be used as a marker to substantiate early stages of the RPE
differentiation process (see Table 4).
Whilst further reducing the present invention to practice, the present inventors
identified additional proteins which are secreted by RPE cells which may be used, in
some embodiments, as a signature to define the cells.
Thus, according to one aspect of the t invention there is provided a
method of qualifying whether a cell population is a suitable therapeutic for treating an
eye condition, comprising analyzing ression of premelanosome protein (PMEL
l7) and at least one ptide selected from the group consisting of cellular
retinaldehyde binding protein (CRALBP), lecithin retinol acyltransferase {LRAT) and
sex determining region Y—box 9 (SOX 9) in the population of cells, wherein when the
number of cells that coexpress the PMELl7 and the at least one polypeptide is above a
predetermined level, the cell population is qualified as being a suitable therapeutic for
treating a retinal disorder.
According to another aspect, there is provided a method of qualifying whether a
cell tion is a suitable therapeutic for treating an eye condition, comprising
analyzing co-expression of cellular retinaldehyde binding protein (CRALBP) and at
least one polypeptide selected from the group consisting of premelanosome protein
(PMEL17), lecithin retinol ansferase (LRAT) and sex determining region Y—box 9
(SOX 9) in the population of cells, wherein when the number of cells that ress
the CRALBP and the at least one polypeptide is above a predetermined level, the cell
population is qualified as being a suitable therapeutic for treating an eye condition.
As used herein, the phrase “suitable therapeutic” refers to the ility of the
cell population for treating eye conditions. Cells which are therapeutic may exert their
effect through any one of a multiple mechanisms. One exemplary ism is trophic
supportive effect promoting the survival of degenerating photoreceptors or other cells
within the retina. Therapeutic RPE cells may also exert their effect h a
ration mechanism replenishing mal—functioning and/or degenerating host RPE
cells. According to one embodiment, the RPE cells are mature and have the functional
capability of phagocytosing outer shedded segments of photoreceptors which include
rhodopsin. According to another embodiment, the RPE cells are not fully mature.
Eye conditions for which the cell populations serve as therapeutics e, but
are not limited to retinal diseases or disorders lly associated with l
dysfunction, retinal injury, and/or loss of retinal t epithelium. A non—limiting list
of conditions which may be treated in accordance with the invention comprises retinitis
pigmentosa, lebers congenital amaurosis, hereditary or acquired macular degeneration,
age related macular degeneration (AMD), Best disease, retinal detachment, gyrate
atrophy, choroideremia, pattern dystrophy as well as other dystrophies of the RPE,
Stargardt disease, RPE and retinal damage due to damage caused by any one of photic,
laser, inflammatory, ious, radiation, neo vascular or tic injury.
As mentioned, the method of this aspect of the invention is carried out by
measuring the amount (e.g. percent cells) sing premelanosome protein (PMELl7;
SwissProt No. P40967) and at least one polypeptide selected from the group consisting
of cellular retinaldehyde g protein (CRALBP; SwissProt No. P1227l), lecithin
retinol acyltransferase (LRAT; SwissProt No. ) and sex determining region Y-
box 9 (SOX 9; P48436).
Alternatively, the method of this aspect is carried out by measuring CRALBP
(CRALBP; SwissProt No. Pl227l) and at least one polypeptide selected from the group
consisting of lecithin l acyltransferase (LRAT; SwissProt No. 095327), sex
determining region Y—box 9 (SOX 9; ) and PMEL17 (SwissProt No. P40967).
Thus, for example, CRALBP and PMEL17 may be measured; PMEL17 and
LRAT may be measured, or PMEL17 and SOX9 may be measured. Alternatively,
CRALBP and LRAT may be measured, or CRALBP and SOX9 may be measured.
It will be appreciated that more than two of the polypeptides mentioned herein
can be measured, for example three of the above mentioned polypeptides or even all
four of the above mentioned polypeptides.
Methods for analyzing for expression of the above mentioned polypeptides
typically involve the use of antibodies which specifically recognize the antigen.
Commercially available antibodies that recognize CRALBP include for example those
manufactured by Abcam (e.g. ab15051 and abl89329, clone B2). Commercially
available antibodies that recognize PMEL17 include for example those ctured by
Abcam (e.g. abl37062 and abl89330, clone EPR4864). Commercially available
antibodies that recognize LRAT include for example those manufactured by Millipore
(e.g. MABN644). cially available dies that recognize SOX9 include for
example those ctured by Abcam (e.g. ab185230). The analyzing may be d
out using any method known in the art including flow try, Western Blot,
immunocytochemistry, radioimmunoassay, PCR, etc.
For flow cytometry, the antibody may be attached to a fluorescent moiety and
analyzed using a fluorescence-activated cell sorter (FACS). Alternatively, the use of
secondary antibodies with fluorescent moieties is envisioned.
It will be appreciated that since the polypeptides which are analyzed are
intracellular polypeptides, lly the cells are permeabilized so that the antibodies are
capable of binding to their targets. Cells may be fixed first to ensure stability of soluble
ns or antigens with a short half—life. This should retain the target protein in the
original ar location. Antibodies may be prepared in permeabilization buffer to
ensure the cells remain permeable. It will be appreciated that when gating on cell
populations, the light r profiles of the cells on the flow cytometer will change
considerably after permeabilization and fixation.
Methods of permeabilizing the cell membrane are known in the art and include
for example:
1. Formaldehyde followed by ent: Fixation in formaldehyde (e.g. no more
than 4.5 % for 10—15 min (this will ize proteins), followed by disruption of
membrane by detergent such as Triton or NP—40 (0.1 to 1% in PBS), Tween 20 (0.1 to
1% in PBS), Saponin, nin and Leucoperm (e.g. 0.5% v/v in PBS);
2. dehyde (e.g. no more than 4.5 %) followed by methanol;
3. Methanol followed by detergent (e.g. 80 % methanol and then 0.1 % Tween
);
4. Acetone fixation and permeabilization.
As used herein, the term "flow cytometry" refers to an assay in which the
proportion of a material (e.g. RPE cells comprising a particular marker) in a sample is
determined by labeling the al (e.g., by binding a labeled antibody to the material),
g a fluid stream containing the material to pass through a beam of light,
separating the light emitted from the sample into constituent wavelengths by a series of
filters and mirrors, and detecting the light.
A multitude of flow cytometers are commercially available ing for e.g.
Becton Dickinson FACScan, Navios Flow Cytometer (Beckman Coulter
serial#AT15119 RHE9266 and FACScalibur (BD Biosciences, Mountain View, CA).
Antibodies that may be used for FACS analysis are taught in Schlossman S, l L,
et al., [Leucocyte Typing V. New York: Oxford
University Press; 1995] and are widely commercially available.
It will be appreciated that the expression level of the above mentioned
polypeptides may be effected on the RNA level as well as the protein level. Exemplary
methods for determining the expression of a polypeptide based on the RNA level
include but are not limited to PCR, RT—PCR, Northern Blot etc.
In order to qualify that the cells are useful as a therapeutic, the amount of at least
two of the polypeptides ressed in the cells should be increased above a
statistically significant level as compared to non—RPE cells (e.g. non—differentiated
embryonic stem cells).
According to a ular embodiment, in order to qualify that the cells are
useful as a eutic, at least 80 % of the cells of the population should s
detectable levels of PMEL17 and one of the above ned polypeptides (e.g.
CRALBP), more preferably at least 85 % of the cells of the population should s
detectable levels of PMEL17 and one of the above mentioned polypeptides (e.g.
CRALBP), more preferably at least 90 % of the cells of the population should express
detectable levels of PMEL17 and one of the above mentioned polypeptides (e.g.
CRALBP), more preferably at least 95 % of the cells of the population should express
able levels of PMEL17 and one of the above mentioned polypeptides (e.g.
CRALBP), more preferably 100 % of the cells of the population should express
detectable levels of PMEL17 and one of the above mentioned polypeptides (e.g.
CRALBP as assayed by a method known to those of skill in the art (e.g. FACS).
According to another embodiment, in order to qualify that the cells are useful as
a therapeutic, the level of CRALBP and one of the above mentioned polypeptides (e.g.
PMEL17) coexpression (e.g. as ed by the mean fluorescent intensity) should be
increased by at least two fold, more preferably at least 3 fold, more preferably at least 4
fold and even more preferably by at least 5 fold, at least 10 fold, at least 20 fold, at least
fold, at least 40 fold, at least 50 as compared to non—differentiated ESCs.
According to a particular embodiment, in order to qualify that the cells are
useful as a therapeutic, at least 80 % of the cells of the population should express
detectable levels of CRALBP and one of the above mentioned polypeptides (e.g.
), more preferably at least 85 % of the cells of the population should express
detectable levels of CRALBP and one of the above mentioned polypeptides (e.g.
PMEL17), more preferably at least 90 % of the cells of the population should s
detectable levels of CRALBP and one of the above mentioned polypeptides (e.g.
PMEL17), more preferably at least 95 % of the cells of the tion should express
detectable levels of CRALBP and one of the above mentioned polypeptides (e.g.
PMEL17), more preferably 100 % of the cells of the population should express
detectable levels of CRALBP and one of the above mentioned polypeptides (e.g.
PMEL17 as assayed by a method known to those of skill in the art (e.g. FACS).
In addition, the cell may be qualified in vivo in animal models. One such model
is the Royal College of Surgeons (RCS) rat model. Following transplantation, the
WO 08239
therapeutic effect of the cells may be analyzed using methods which include fundus
imaging, optokinetic tracking thresholds (OKT), electroretinogram (ERG), ogy,
cone counting and rhodopsin ingestion. These methods are further described in Example
, herein below.
The cells may be qualified or characterized in additional ways including for
example karyotype analysis, morphology, cell number and viability, potency (barrier
function and polarized secretion of PEDF and VEGF), level of residual hESCs, gram
staining and ity. Exemplary assays which may be performed are described in
Example 4.
In addition, the cells may be analyzed for barrier on and their level of
growth factor secretion in a polarized manner (e.g. t epithelium—derived factor
(PEDF) or VEGF, cytokines, interleukins and/or chemokines).
For is of secreted PEDF, supernatant is ted from es of the
cells, and cells are harvested and counted. The amount of PEDF in the cell’s culture
supematants may be quantified by using a PEDF ELISA assay (such as ELISAquantTM
PEDF Sandwich ELISA Antigen Detection Kit, BioProductsMD, PED613) according to
the manufacturer's protocol.
In addition, the direction of ion of PEDF and VEGF may be analyzed in
the cells. This may be effected using a ell assay as illustrated in Figure 28. Prior
to or following qualification, the cells may be preserved according to methods known in
the art (e. g. frozen or cryopreserved) or may be directly administered to the subject.
The present invention contemplates analyzing cell populations which comprise
retinal pigment epithelial (RPE) cells from any source. Thus, the cell tions may
comprise RPE cells obtained from a donor (i.e. native RPE cells of the pigmented layer
of the retina) or may comprise RPE cells which were ex—vivo differentiated from a
population of stem cells (hSC—derived RPE cells, such as pluripotent stem cells — e.g.
human embryonic stem cells). According to another embodiment, the RPE cells are
obtained by transdifferentiation — see for example Zhang et al., Protein Cell 2014,
(1):48—58, the contents of which are incorporated herein by reference.
According to one ment, the RPE cells that are analyzed do not express
Pax6.
According to another embodiment, the RPE cells that are analyzed express Pax6.
“Retinal pigment epithelium cells”, “RPE cells”, “RPEs”, which may be used
hangeably as the context allows, refers to cells of a cell type functionally similar
to that of native RPE cells which form the pigment epithelium cell layer of the retina
(e.g. upon transplantation within an eye, they exhibit functional activities r to
those of native RPE cells).
According to one embodiment, the RPE cell expresses at least one, two, three,
four or five markers of mature RPE cells. Such s include, but are not limited to
CARLBP, RPE65, PEDF, PMEL17, Bestrophin and tyrosinase. Optionally, RPE cells
may also express a marker of an RPE progenitor — e. g. MITF. In another embodiment,
the RPE cells express FAX—6. In another embodiment, the RPE cells express at least
one marker of a retinal progenitor cell including, but not d to OTX2, SIX3, SIX6
and LHX2.
According to yet another embodiment, the RPE cells are those that are
differentiated from nic stem cells according to the method described in the
Examples section herein below, the ts of the Examples being as if included in the
specification itself.
As used herein, the phrase “markers of mature RPE cells” refers to antigens (e.g.
proteins) that are elevated (e.g. at least 2 fold, at least 5 fold, at least 10 fold) in mature
RPE cells with respect to non RPE cells or immature RPE cells.
As used herein the phrase “markers of RPE progenitor cells” refers to antigens
(e.g. ns) that are elevated (e.g. at least 2 fold, at least 5 fold, at least 10 fold) in
RPE progenitor cells with respect to non RPE cells.
ing to another ment, the RPE cells have a morphology similar to
that of native RPE cells which form the pigment epithelium cell layer of the retina i.e.
pigmented and/or have a characteristic polygonal shape.
According to still another embodiment, the RPE cells are capable of treating
diseases such as macular degeneration.
ing to still another embodiment, the RPE cells fulfill at least 1, 2, 3, 4 or
all of the requirements listed herein above.
The term "hSC—derived RPE cells" is used herein to denote RPE cells that are
obtained by directed differentiation from hSCs. In accordance with a preferred
embodiment, the hSC—derived RPE cells are functional RPE cells as exhibited by
parameters defined hereinbelow. The term ”directed differentiation" is used
interchangeably with the term "RPE induced differentiation" and is to be understood as
meaning the process of manipulating hSCs under culture conditions which
induce/promote differentiation into RPE cell type.
According to a particular embodiment, the RPE cells are obtained by directed
differentiation of hSCs in the presence of one or more members of the TGFB
superfamily, and exhibit at least one of the following characteristics:
— during differentiation, the cultured cells respond to TGFB signaling;
— the RPE cells express markers tive of terminal entiation, e.g.
bestrophin 1, CRALBP and/or RPE65;
— following transplantation (i.e. in situ), the RPE cells exhibit trophic
effect supporting eceptors adjacent to RPE cells;
— further, in situ the RPE cells are capable of functioning with
phagocytosis of shed photoreceptor outer segments as part of the normal renewal
process of these eceptors;
— further, in situ the RPE cells are capable of generating a retinal barrier
and functioning in the visual cycle.
As used herein, the phrase “stem cells” refers to cells which are capable of
ing in an undifferentiated state (e.g., pluripotent or multipotent stem cells) for
extended periods of time in culture until induced to differentiate into other cell types
having a particular, specialized function (e.g., fully differentiated cells). Preferably, the
phrase “stem cells” encompasses embryonic stem cells (ESCs), d pluripotent
stem cells (iPS), adult stem cells, hymal stem cells and hematopoietic stem cells.
According to a ular embodiment, the RPE cells are d from
pluripotent stem cells ing human embryonic stem cells or induced otent
stem cells.
The phrase “embryonic stem cells” refers to embryonic cells which are capable
of differentiating into cells of all three embryonic germ layers (i. 6., endoderm, ectoderm
and mesoderm), or remaining in an undifferentiated state. The phrase “embryonic stem
cells” may comprise cells which are obtained from the embryonic tissue formed after
gestation (e.g., blastocyst) before implantation of the embryo (i.e., a pre—implantation
blastocyst), extended blastocyst cells (EBCs) which are obtained from a post—
implantation/pre—gastrulation stage blastocyst (see WO2006/040763) and embryonic
germ (EG) cells which are obtained from the genital tissue of a fetus any time during
gestation, preferably before 10 weeks of gestation. The embryonic stem cells of some
embodiments of the ion can be obtained using well—known ulture s.
For e, human embryonic stem cells can be isolated from human blastocysts.
Human blastocysts are typically obtained from human in viva preimplantation embryos
or from in vitro fertilized (IVF) embryos. Alternatively, a single cell human embryo can
be expanded to the blastocyst stage. For the isolation of human ES cells, the zona
pellucida is d from the cyst and the inner cell mass (ICM) is isolated by
surgery, in which the trophectoderm cells are lysed and removed from the intact ICM by
gentle pipetting. The ICM is then plated in a tissue culture flask containing the
appropriate medium which enables its outgrowth. Following 9 to 15 days, the ICM
derived outgrowth is dissociated into clumps either by a mechanical dissociation or by
an enzymatic degradation and the cells are then re-plated on a fresh tissue culture
medium. es demonstrating undifferentiated morphology are individually ed
by micropipette/stem cell tool, mechanically dissected into fragments/clumps, and re-
plated. Resulting ES cells are then routinely split every 4—7 days. For further details on
methods of preparation human ES cells see Reubinoff et al., Nat Biotechnol 2000, May:
18(5): 559; Thomson et al., [US Patent No. 5,843,780; Science 282: 1145, 1998; Curr.
Top. Dev. Biol. 38: 133, 1998; Proc. Natl. Acad. Sci. USA 92: 7844, 1995]; Bongso et
al., [Hum Reprod 4: 706, 1989]; and Gardner et al., [Fertil. Steril. 69: 84, 1998].
It will be appreciated that commercially available stem cells can also be used
according to some embodiments of the invention. Human ES cells can be purchased
from the NIH human embryonic stem cells registry text Transfer
Protocol://grants(dot)nih(dot)gov/stem_cells/registry/current(dot)htm] and other
European registries. Non—limiting examples of cially available embryonic stem
cell lines are HAD-C102, ESI, BGOl, BG02, BG03, BG04, CY12, CY30, CY92, CY10,
TE03, TE32, CHB-4, CHB-5, CHB-6, CHB-8, CHB-9, CHB-10, CHB-ll, CHB-12,
HUES 1, HUES 2, HUES 3, HUES 4, HUES 5, HUES 6, HUES 7, HUES 8, HUES 9,
HUES 10, HUES 11, HUES 12, HUES 13, HUES 14, HUES 15, HUES 16, HUES 17,
HUES 18, HUES 19, HUES 20, HUES 21, HUES 22, HUES 23, HUES 24, HUES 25,
HUES 26, HUES 27, HUES 28, CyT49, RUES3, WA01, UCSF4, NYUESl, NYUES2,
NYUES3, , NYUESS, NYUES6, NYUES7, UCLA 1, UCLA 2, UCLA 3,
WA077 (H7), WA09 (H9), WA13 (H13), WA14 (H14), HUES 62, HUES 63, HUES
64, CTl, CT2, CT3, CT4, MA135, Eneavour—2, WIBRl, WIBR2, WIBR3, WIBR4,
WIBRS, WIBR6, HUES 45, Shef 3, Shef 6, BJNhem19, BJNhem20, SA001, SA001.
In addition, ES cells can be obtained from other species as well, including
mouse (Mills and Bradley, 2001), golden hamster [Doetschman et al., 1988, Dev Biol.
127: 224—7], rat [Iannaccone et al., 1994, Dev Biol. 163: ] rabbit [Giles et al.
1993, Mol Reprod Dev. 36: 130—8; Graves & Moreadith, 1993, Mol Reprod Dev. 1993,
36: 424—33], several domestic animal species [Notarianni et al., 1991, J Reprod Fertil
Suppl. 43: 255—60; Wheeler 1994, Reprod Fertil Dev. 6: 563—8; Mitalipova et al., 2001,
Cloning. 3: 59—67] and non—human primate species s monkey and marmoset)
[Thomson et al., 1995, Proc Natl Acad Sci U S A. 92: 7844—8; Thomson et al., 1996,
Biol Reprod. 55: 254—9].
Extended blastocyst cells (EBCs) can be obtained from a blastocyst of at least
nine days post fertilization at a stage prior to gastrulation. Prior to culturing the
blastocyst, the zona pellucida is digested [for e by Tyrode’s acidic solution
(Sigma Aldrich, St Louis, MO, USA)] so as to expose the inner cell mass. The
blastocysts are then cultured as whole embryos for at least nine and no more than
fourteen days post fertilization (i.e., prior to the lation event) in vitro using
standard embryonic stem cell culturing methods.
r method for preparing ES cells is described in Chung et al., Cell Stem
Cell, Volume 2, Issue 2, 113—117, 7 February 2008. This method comprises removing a
single cell from an embryo during an in vitro fertilization process. The embryo is not
destroyed in this process.
Yet another method for preparing ES cells is by parthenogenesis. The embryo is
also not destroyed in the process.
Currently practiced ES culturing methods are mainly based on the use of feeder
cell layers which e factors needed for stem cell proliferation, While at the same
time, inhibit their differentiation. Exemplary feeder layers include Human embryonic
fibroblasts, adult fallopian epithelial cells, primary mouse embryonic fibroblasts
(PMEF), mouse embryonic fibroblasts (MEF), murine fetal fibroblasts (MFF), human
nic last (HEF), human fibroblasts obtained from the differentiation of
human embryonic stem cells, human fetal muscle cells (HFM), human fetal skin cells
(HFS), human adult skin cells, human foreskin fibroblasts (HFF), human umbilical cord
fibroblasts, human cells obtained from the umbilical cord or ta, and human
marrow stromal cells (hMSCs). Growth s may be added to the medium to
maintain the ESCs in an undifferentiated state. Such growth factors include bFGF
and/or TGFB. In another embodiment, agents may be added to the medium to maintain
the hESCs in a naive undifferentiated state — see for e Kalkan et al., 2014, Phil.
Trans. R. Soc. B, 369: 20130540.
Feeder cell free systems have also been used in ES cell culturing, such systems
utilize matrices supplemented with serum replacement, cytokines and growth factors
(including IL6 and e 1L6 receptor chimera) as a replacement for the feeder cell
layer. Stem cells can be grown on a solid surface such as an extracellular matrix (e.g.,
MatrigelRTM or laminin) in the presence of a culture medium — for example the Lonza L7
system, mTeSR, StemPro, XFKSR, E8). Unlike feeder-based cultures which require the
simultaneous growth of feeder cells and stem cells and which may result in mixed cell
populations, stem cells grown on feeder—free systems are easily separated from the
surface. The culture medium used for growing the stem cells ns factors that
effectively inhibit entiation and promote their growth such as MEF—conditioned
medium and bFGF. However, commonly used feeder—free culturing systems e an
animal—based matrix (e.g., MatrigelRTM) supplemented with mouse or bovine serum, or
with MEF conditioned medium [Xu C, et al. (2001). Feeder—free growth of
undifferentiated human embryonic stem cells. Nat Biotechnol. 19: 971—4] which present
the risk of animal pathogen cross—transfer to the human ES cells, thus compromising
future clinical applications.
Numerous methods are known for differentiating ESCs towards the RPE lineage
and include both directed entiation protocols such as those described in WO
2008/129554, 2013/184809 and spontaneous differentiation ols such as those
described in U.S. Patent No. 8,268,303 and U.S. Patent application 20130196369, the
contents of each being incorporated by reference.
According to a ular embodiment, the RPE cells are generated from ESC
cells using a directed differentiation ol — for example according to that disclosed
in the Example section.
In one exemplary differentiation protocol, the embryonic stem cells are
differentiated towards the RPE cell lineage using a first differentiating agent and then
further differentiated towards RPE cells using a member of the transforming growth
factor—B (TGFB) amily, (e.g. TGFBl, TGFBZ, and TGFB3 subtypes, as well as
homologous ligands ing activin (e.g., activin A, activin B, and activin AB), nodal,
anti—mullerian hormone (AMH), some bone morphogenetic proteins (BMP), e.g. BMP2,
BMP3, BMP4, BMPS, BMP6, and BMP7, and growth and differentiation factors
(GDF)).
According to a ular embodiment, the TGFB superfamily member is
selected from the group ting of TGFBI, activin A and TGFB3.
According to a specific embodiment, the member of the transforming growth
—B (TGFB) superfamily is activin A — e.g. between 20—200 ng/ml, e.g. 100—180
ng/ml.
The first differentiating agent promotes differentiation towards the RPE lineage.
For e, the first differentiating agent may promote differentiation of the
pluripotent stem cells into neural progenitors. Such cells may express neural precursor
markers such as PAX6.
According to a particular embodiment, the first differentiating agent is
nicotinamide (NA) — e.g. between l—lOO mM, 5—50 mM, 5—20 mM, e.g. 10 mM.
NA, also known as “niacinamide”, is the amide derivative form of Vitamin B3
(niacin) which is thought to preserve and improve beta cell function. NA has the
chemical formula C6H6N20. NA is essential for growth and the sion of foods to
energy, and it has been used in arthritis ent and diabetes treatment and prevention.
\ \O
N 25
Nicotinamide (NA)
According to a particular embodiment, the namide is a namide
derivative or a namide mimic. The term ative of nicotinamide (NA)" as used
herein denotes a compound which is a chemically modified derivative of the natural
NA. In one embodiment, the chemical modification may be a substitution of the
pyridine ring of the basic NA structure (via the carbon or nitrogen member of the ring),
via the nitrogen or the oxygen atoms of the amide moiety. When substituted, one or
more hydrogen atoms may be replaced by a substituent and/or a substituent may be
attached to a N atom to form a tetravalent positively charged nitrogen. Thus, the
nicotinamide of the present invention includes a tuted or non—substituted
nicotinamide. In another embodiment, the al modification may be a deletion or
replacement of a single group, e.g. to form a thiobenzamide analog of NA, all of which
being as appreciated by those versed in organic chemistry. The derivative in the context
of the invention also includes the nucleoside derivative of NA (e.g. nicotinamide
adenine).
A variety of derivatives of NA are described, some also in tion with an
inhibitory activity of the PDE4 enzyme 068233; WOO2/060875;
GB2327675A), or as VEGF—receptor tyrosine kinase inhibitors (WOOl/55114). For
example, the process of preparing 4—aryl—nicotinamide derivatives (W005/014549).
Other exemplary nicotinamide derivatives are disclosed in WOOl/55114 and
EP2128244.
Nicotinamide mimics include modified forms of nicotinamide, and chemical
s of nicotinamide which recapitulate the effects of nicotinamide in the
differentiation and tion of RPE cells from pluripotent cells. Exemplary
nicotinamide mimics include benzoic acid, 3—aminobenzoic acid, and 6—
aminonicotinamide. Another class of compounds that may act as nicotinamide mimics
are inhibitors of poly(ADP—ribose) polymerase (PARP). Exemplary PARP inhibitors
include 3-aminobenzamide, Iniparib (B31 201), Olaparib (AZD-2281), rib
(AG014699, PF- 01367338), Veliparib (ABT-888), CEP 9722, MK 4827, and BMN-
673.
According to a particular ment, the differentiation is effected as follows:
a) culture of ESCs in a medium comprising a first differentiating agent (e.g.
nicotinamide); and
b) culture of cells obtained from step a) in a medium comprising a member of
the TGFB superfamily (e.g. activin A) and the first differentiating agent (e.g.
nicotinamide).
Preferably step (a) is effected in the absence of the member of the TGFB
superfamily.
The above described protocol may be continued by culturing the cells obtained
in step (b) in a medium comprising the first differentiating agent (e.g. nicotinamide), but
devoid of a member of the TGFB superfamily (e.g. activin A). This step is referred to
herein as step (c).
The above described protocol is now described in further detail, with additional
embodiments.
The differentiation process is d once sufficient quantities of ESCs are
obtained. They are typically removed from the adherent cell culture (e.g. by using
collagenase A, dispase, TrprE select, EDTA) and plated onto a non-adherent substrate
(e.g. Hydrocell non—adherent cell culture plate) in the presence of nicotinamide (and the
absence of activin A). Exemplary concentrations of nicotinamide are between 1—100
mM, 5—50 mM, 5—20 mM, e.g. 10 mM, Once the cells are plated onto the non—adherent
ate, the cell culture may be referred to as a cell suspension, preferably free
floating clusters in a sion culture, i.e. aggregates of cells derived from human
embryonic stem cells (hESCs). The cell clusters do not adhere to any ate (e.g.
culture plate, carrier). Sources of free floating stem cells were previously described in
WC 06/070370, which is herein incorporated by reference in its entirety. This stage may
be effected for a minimum of 1 day, more preferably two days, three days, 1 week or
even 10 days. Preferably, the cells are not ed for more than 2 weeks in suspension
together with the nicotinamide (and in the absence of the TGFB superfamily member
e. g. activin A).
According to a preferred embodiment, when the cells are cultured on the non-
adherent substrate, the heric oxygen conditions are manipulated such that the
percentage is equal or less than about 20 %, 15 %, 10 %, more ably less than
about 9 %, less than about 8 %, less than about 7 %, less than about 6 % and more
preferably about 5 % (e.g. between 1 % — 20 %, l %—10 % or 0-5 %).
Examples of non—adherent cell culture plates include those manufactured by
Hydrocell (e.g. Cat No. 174912), Nunc etc.
Typically, the clusters comprise at least 50-500,000, 50-100,000, 50-50,000, 50-
,000, 50-5000, 50—1000 cells. According to one embodiment, the cells in the clusters
are not organized into layers and form irregular shapes. In one embodiment, the clusters
are devoid of pluripotent embryonic stem cells. In another embodiment, the clusters
comprise small amounts of pluripotent embryonic stem cells (e.g. no more than 5 %, or
no more than 3 % (e.g. 0.01—2.7%) cells that co—express OCT4 and TRA 1—60 at the
protein level). Typically, the clusters comprise cells that have been partially
differentiated under the influence of nicotinamide. Such cells may express neural
precursor markers such as PAX6. The cells may also express markers of progenitors of
other lineages such as for example alpha—feto protein, MIXLl and Brachyuri.
The clusters may be dissociated using enzymatic or non—enzymatic methods
(e.g., ical) known in the art. According to one ment, the cells are
dissociated such that they are no longer in clusters — e.g. aggregates or clumps of 2—
0 cells, 2—50,000 cells, 2—10,000 cells, 2—5000 cells, 2-1000 cells, 2—500 cells, 2-
100 cells, 2—50 cells. According to a particular embodiment, the cells are in a single cell
suspension.
The cells (e.g. iated cells) are then plated on an adherent substrate and
cultured in the presence of nicotinamide e.g. between l—100 mM, 5—50 mM, 5—20 mM,
e.g. 10 mM (and the absence of activin A). This stage may be effected for a minimum
of 1 day, more preferably two days, three days, 1 week or even 14 days. Preferably, the
cells are not cultured for more than 1 week in the presence of nicotinamide on the
adherent cell e (and in the absence of activin).
Altogether, the cells are typically exposed to namide, (at concentrations
between l-lOO mM, 5—50 mM, 5-20 mM, e.g. 10 mM), for about 2—3 weeks, and
preferably not more than 4 weeks prior to the addition of the second differentiating
factor (e. g. Activin A).
es of nt substrates include but are not limited to collagen,
fibronectin, n, (e.g. laminin 521).
Following the first stage of directed entiation (i.e. culture in the ce
of nicotinamide (e.g. 10 mM) under non—adherent culture conditions under low oxygen
atmospheric conditions ed by ing on an adherent substrate in the presence
of nicotinamide under low oxygen atmospheric conditions), the semi—differentiated cells
are then subjected to a further stage of differentiation on the adherent substrate -
culturing in the presence of nicotinamide (e.g. 10 mM) and activin A (e.g. 20—200
ng/ml, 100—200 ng/ml, e.g. 140 ng/ml, 150 ng/ml, 160 ng/ml or 180 ng/ml). This stage
may be effected for 1 day to 10 weeks, 3 days to 10 weeks, 1 week to 10 weeks, one
week to eight weeks, one week to four weeks, for example for at least one week, at least
two weeks, at least three weeks, at least four weeks, at least five weeks, at least six
weeks, at least seven weeks or even eight weeks. Preferably this stage is effected for
about two weeks. According to one embodiment, this stage of differentiation is also
effected at low atmospheric oxygen conditions — i.e. less than about 20 %, 15 %, 10 %,
more preferably less than about 9 %, less than about 8 %, less than about 7 %, less than
about 6 % and more preferably about 5 % (e.g. between 1 % — 20 %, l %—10 % or 0-5
Following the second stage of directed differentiation (i.e. e in the
presence of nicotinamide and activin A on an adherent substrate), the further
differentiated cells may optionally be subjected to a subsequent stage of differentiation
on the adherent substrate — ing in the presence of nicotinamide (e.g. between 1—100
mM, 5—50 mM, 5—20 mM, e.g. 10 mM), in the e of activin A. This stage may be
effected for at least one day, 2 days, 3 days, 1 week, at least two weeks, at least three
weeks or even four weeks. Preferably this stage is effected for about one week. This
stage of differentiation may be effected at low (i.e. less than about 20 %, 15 %, 10 %,
more preferably less than about 9 %, less than about 8 %, less than about 7 %, less than
about 6 % and more preferably about 5 % (e.g. between 1 % — 20 %, l %—10 % or 0-5
%) or normal atmospheric oxygen conditions or a combination of both (i.e. initially at
low atmospheric oxygen ions and uently when lightly pigmented cells are
ed, at normal oxygen conditions).
According to a particular embodiment, when the atmospheric oxygen conditions
are returned to normal atmospheric conditions the cells are cultured for at least one
more day (e.g. up to two weeks) in the presence of nicotinamide (e.g. 10 mM) and in the
e of activin A.
2015/051269
The basic medium in accordance with the invention is any known cell culture
medium known in the art for supporting cells growth in vitro, typically, a medium
comprising a defined base solution, which includes salts, sugars, amino acids and any
other nutrients required for the maintenance of the cells in the culture in a Viable state.
Non-limiting examples of commercially available basic media that may be utilized in
accordance with the invention comprise Nuristem (without bFGF and TGFB for ESC
entiation, with bFGF and TGFB for ESC expansion) NeurobasalTM, KO—DMEM,
DMEM, DMEM/Fl2, Lonza L7 system, mTeSR, StemPro, XF KSR, E8, oTM
Stem Cell Growth Medium, or X—VivoTM. The basic medium may be supplemented
with a variety of agents as known in the art dealing with cell cultures. The following is a
non—limiting nce to various supplements that may be ed in the culture
system to be used in accordance with the present disclosure:
— serum or with a serum replacement containing , such as, without
being limited thereto, knock out serum replacement (KOSR), Nutridoma-CS, TCHTM,
N2, N2 derivative, or B27 or a combination;
— an extracellular matrix (ECM) component, such as, without being limited
thereto, fibronectin, laminin, collagen and gelatin. The ECM may them be used to carry
the one or more s of the TGFB superfamily of growth s;
— an antibacterial agent, such as, without being limited thereto, penicillin
and streptomycin;
— non—essential amino acids , neurotrophins which are known to
play a role in promoting the survival of SCs in culture, such as, without being limited
thereto, BDNF, NT3, NT4.
According to a preferred embodiment, the medium used for differentiating the
ESCs is Nuristem medium gical Industries, 05—102—1A or 05—100—1A).
According to a particular embodiment, differentiation of ESCs is effected under
xeno free conditions.
According to one embodiment, the proliferation/growth medium is devoid of
xeno contaminants i.e. free of animal derived components such as serum, animal
derived growth factors and albumin. Thus, according to this embodiment, the culturing
is performed in the absence of xeno contaminants.
WO 08239
Other methods for culturing ESCs under xeno free conditions are provided in
U.S. Patent Application Publication No. 20130196369, the contents of which are
orated in their entirety.
During differentiation steps, the embryonic stem cells may be monitored for
their differentiation state. Cell differentiation can be determined upon examination of
cell or tissue—specific markers which are known to be indicative of differentiation.
Tissue/cell specific markers can be detected using immunological techniques
well known in the art [Thomson JA et al., (1998). e 282: 1145—7]. Examples
e, but are not limited to, flow cytometry for membrane—bound or intracellular
markers, immunohistochemistry for extracellular and ellular markers and
enzymatic immunoassay, for secreted molecular markers (e.g. PEDF).
Thus, according to another aspect of the present invention there is provided a
method of generating retinal epithelial cells sing:
(a) ing pluripotent stem cells in a medium sing a differentiating
agent so as to generate differentiating cells, wherein the medium is devoid of a member
of the transforming growth factor B (TGF [3) superfamily;
(b) culturing the differentiating cells in a medium comprising the member of
the transforming growth factor [3 (TGF [3) superfamily and the entiating agent to
generate cells which are further differentiated towards the RPE lineage;
(c) analyzing the secretion of Pigment epithelium—derived factor (PEDF)
from the cells which are further differentiated towards the RPE lineage; and
(d) ing the cells which are further differentiated towards the RPE
lineage in a medium comprising a differentiating agent so as to generate RPE cells,
wherein the medium is devoid of a member of the transforming growth factor B (TGF [3)
superfamily, wherein step (d) is effected when the amount of the PEDF is above a
predetermined level.
Preferably, step (d) is effected when the level of PEDF is above 100 ng/ml/day,
200 ng/ml/day, 300 ng/ml/day, 400 ng/ml/day, or 500 ng/ml/day.
Another method for determining potency of the cells during or following the
entiation process is by analyzing barrier function and polarized PEDF and VEGF
secretion, as illustrated in Example 4, herein below.
Once the cells are promoted into RPE cells, they may be selected and/or
expanded.
According to a particular embodiment, the selection is based on a negative
selection — i.e. removal of non—RPE cells. This may be done mechanically by removal of
non-pigmented cells or l of non—polygonal cells or by use of e markers.
According to another embodiment, the selection is based on a positive selection
i.e. selection based on morphology (e.g. pigmented cells and/or polygonal cells). This
may be done by visual analysis or use of surface markers.
According to still another embodiment, the selection is based first on a negative
selection and then on a positive selection.
Expansion of RPE cells may be effected on an extra cellular matrix, e.g. gelatin,
collagen or poly—D—lysine and laminin. For expansion, the cells may be cultured in
serum—free KOM, serum comprising medium (e.g. DMEM + 20 %) or Nuristem
medium (06-5 1021A ical Industries). ally, the cells may be exposed to
nicotinamide during the expansion phase — at concentrations between l—lOO mM, 5-50
mM, 5—20 mM, e.g. 10 mM. Under these e conditions, the pigmented cells reduce
pigmentation and e a fibroid—like morphology. Following further ged
culture and proliferation into high—density es, the cells re—acquire the characteristic
polygonal shape morphology and preferably also pigmentation of RPE cells.
The RPE cells may be expanded in suspension or in a monolayer. The expansion
of the RPE cells in yer cultures may be modified to large scale expansion in
bioreactors by methods well known to those versed in the art.
The population of RPE cells generated according to the s described
herein may be characterized according to a number of different parameters.
Thus, for example, the RPE cells obtained are nal in shape and are
pigmented.
According to one embodiment, at least 70 %, 75 %, 80 %, 85 % 90 %, 95 %, at
least 96 %, at least 97 %, at least 98 %, at least 99 % or even 100 % of the cells of the
RPE cell populations obtained co—express both premelanosome protein 7) and
cellular retinaldehyde binding protein (CRALBP).
Following administration, the cells described herein are capable of forming a
monolayer (as illustrated in Figure 27C).
WO 08239
According to one ment, the trans—epithelial electrical resistance of the
cells in a monolayer is greater than 100 ohms.
Preferably, the trans-epithelial electrical ance of the cells is greater than
150, 200, 250, 300, 300, 400, 500, 600, 700, 800 or even greater than 900 ohms.
ing to a particular embodiment, the TEER is n 100—1000 ohms,
more preferably between 100—900 ohms for e between 200—900 ohms, 300-800
ohms, 300—700 ohms, 400—800 ohms or 400—700 ohms.
Devices for measuring trans—epithelial electrical resistance (TEER) are known in
the art. An exemplary set—up for measuring TEER is illustrated in Figure 28.
It will be appreciated that the cell populations disclosed herein are devoid of
undifferentiated human embryonic stem cells. According to one embodiment, less than
l:250,000 cells are Oct4J'TRA—1—60+ cells, as measured for e by FACS. The cells
also do not express or downregulate expression of GDF3 or TDGF relative to hESCs as
measured by PCR.
Another way of characterizing the cell populations disclosed herein is by marker
sion. Thus, for example, at least 80 %, 85 %, or 90 % of the cells express
Bestrophin l, as measured by immunostaining. According to one embodiment, n
90—95 % of the cells express bestrophin.
ing to another embodiment, at least 80 %, 85 %, 87 %, 89 % or 90 % of
the cells express Microphthalmia—associated transcription factor {MITF), as measured
by immunostaining. For example, between 85—95 % of the cells express MITF.
According to r embodiment, at least 50 %, 55 %, 60 %, 70 %, 75 % 80 %
85 %, 87 %, 89 % or 90 % of the cells express paired box gene 6 (FAX—6) as measured
by FACS.
The cells described herein can also be characterized according to the quantity
and/or type of factors that they secrete. Thus, according to one embodiment, the cells
preferably secrete more than 500, 750, 1000, or even 2000 ng of Pigment epithelium-
derived factor (PEDF) per ml per day, (e.g. following 14 days in culture) as measured
by ELISA.
It will be appreciated that the RPE cells generated herein secrete PEDF and
vascular endothelial growth factor (VEGF) in a polarized manner. According to
particular embodiments, the ratio of apical secretion of PEDF: basal secretion of PEDF
is greater than 1. According to particular embodiments, the ratio of apical secretion of
PEDF: basal secretion of PEDF is greater than 2. According to ular embodiments,
the ratio of apical secretion of PEDF: basal secretion of PEDF is greater than 3. In
addition, the ratio of basal ion of VEGF: apical secretion of VEGF is greater than
1. According to particular embodiments, the ratio of basal ion of VEGF: apical
secretion of VEGF is greater than 1.5, 2 or 2.5.
The cells of the present invention secrete additional factors including for
example angiogenin, the immunomodulatory factors IL—6, sgpl30, MIF, sTNF—Rl,
sTRAIL—R3, MCP—l and Osteoprotegerin, the ellular matrix regulators TIMP—1
and TIMP—2 and the protein Axl.
According to another aspect, at least 80 % of the cells of the cell population co—
express premelanosome protein (PMELl7) and cellular retinaldehyde binding protein
(CRALBP) and r a portion (at least 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %,
80 %, 90 %, 95 %) of the cells secrete/shed each of angiogenin, tissue inhibitor of
metalloproteinase 2 (TIMP 2), soluble glycoprotein 130 0) and soluble form of
the ubiquitous membrane receptor 1 for tumor necrosis factor-0t (sTNF-Rl).
It will be appreciated that in some cases all the cells that co—express
premelanosome protein (PMELl7) and cellular retinaldehyde binding n
(CRALBP) also secrete/shed angiogenin, tissue inhibitor of metalloproteinase 2 (TIMP
2), soluble glycoprotein 130 (sgpl30) and soluble form of the tous ne
receptor 1 for tumor necrosis factor—0t (sTNF—Rl).
In other cases the majority (more than 50 %, 60 %, 70 %, 80, 90 % of the cells
that co—express premelanosome protein (PMELl7) and cellular retinaldehyde binding
n (CRALBP) also secrete/shed angiogenin, tissue inhibitor of metalloproteinase 2
(TIMP 2), soluble glycoprotein 130 (sgpl30) and soluble form of the ubiquitous
membrane receptor 1 for tumor necrosis —0t (sTNF—Rl).
The RPE cells generated herein preferably secrete enin, TIMP2, sgpl30
and sTNF—Rl in a polarized manner.
According to particular embodiments, the ratio of apical secretion of sgpl30:
basal secretion of sgpl30 is greater than 1. According to particular embodiments, the
ratio of apical ion of sgpl30: basal secretion of sgpl30 is greater than 2.
WO 08239
ing to particular embodiments, the ratio of apical secretion of sgp130: basal
secretion of sgpl30 is greater than 3.
Furthermore, the ratio of apical sTNF-Rl: basal sTNF-Rl is greater than 1.
According to particular embodiments, the ratio of apical sTNF—Rl: basal sTNF—Rl is
greater than 2. ing to particular embodiments, the ratio of apical sTNF—Rl: basal
sTNF—Rlis greater than 3.
In addition, the ratio of basal secretion of angiogenin: apical secretion of
angiogenin is greater than 1. According to particular embodiments, the ratio of basal
secretion of angiogenin: apical secretion of angiogenin is greater than 1.5, 2, 2.5 or 3.
Furthermore, the ratio of apical secretion of TIMP2: basal secretion of TllVIP2 is
greater than 1. According to particular embodiments, the ratio of apical secretion of
TIMP2: basal secretion of TIMP2 is r than 2. ing to ular
embodiments, the ratio of apical secretion of TIMP2: basal secretion of TIMP2 is
greater than 3.
The stability of the cells is another characterizing feature. Thus, for example the
amount of PEDF secretion remains stable in the cells following their incubation at 2-8
°C for 6 hours, 8 hours, 10 hours, 12 hours or even 24 hours. Further, the polarized
secretion of PEDF and VEGF s stable following incubation of the cells at 2—8 ”C
for 6 hours, 8 hours, 10 hours, 12 hours or even 24 hours. Further, the TEER of the cells
remains stable in the cells following their tion at 2—8 ”C for 6 hours, 8 hours, 10
hours, 12 hours or even 24 hours.
In another embodiment, the cells are characterized by their therapeutic effect.
Thus, for example the present inventors have shown that the cell tions are
capable of rescuing visual acuity in the RC3 rat following subretinal administration. In
on, the cell tions are capable of rescuing photoreceptors (e.g. cone
photoreceptors) for up to 180 days (in some embodiments at least 180 days) post—
subretinal administration in the RC3 rat.
It would be well appreciated by those versed in the art that the derivation of RPE
cells is of great benefit. They may be used as an in vitro model for the development of
new drugs to promote RPE cell survival, regeneration and function. RPE cells may
serve for high throughput screening for compounds that have a toxic or regenerative
effect on RPE cells. They may be used to uncover mechanisms, new genes, soluble or
membrane—bound factors that are important for the development, differentiation,
maintenance, survival and function of photoreceptor cells.
The RPE cells may also serve as an unlimited source of RPE cells for
transplantation, replenishment and support of malfunctioning or degenerated RPE cells
in retinal degenerations. Furthermore, cally modified RPE cells may serve as a
vector to carry and express genes in the eye and retina after transplantation.
The RPE cells produced by the method of the present disclosure may be used for
large scale and/or long term ation of such cells. To this end, the method of the
invention is to be performed in bioreactors and or cell culture s suitable for large
scale production of cells, and in which undifferentiated hSCs are to be cultivated in
accordance with the invention. General requirements for cultivation of cells in
bioreactors and or cell culture systems are well known to those versed in the art.
Harvesting of the cells may be performed by various methods known in the art.
Non-limiting examples include mechanical dissection and dissociation with papain or
trypsin (e.g. TrprE select). Other methods known in the art are also applicable.
The RPE cells generated as described herein may be transplanted to various
target sites within a subject's eye. In accordance with one embodiment, the
transplantation of the RPE cells is to the subretinal space of the eye, which is the normal
anatomical location of the RPE (between the photoreceptor outer segments and the
choroid). In addition, dependent upon migratory ability and/or positive paracrine s
of the cells, transplantation into additional ocular compartments can be considered
including the inner or outer retina, the l periphery and within the ds.
Retinal diseases which may be treated using the RPE cells described herein
include, but are not d to retinitis pigmentosa, retinoschisis, lattice degeneration,
Best disease, and age related macular degeneration (AMD).
Further, transplantation may be performed by various techniques known in the
art. Methods for performing RPE lants are described in, for example, U.S. Pat.
Nos. 027, 6,045,791, and 5,941,250 and in Eye s Arch Clin Exp Opthalmol
March 1997; :149—58; Biochem s Res Commun Feb. 24, 2000; 268(3):
842—6; Opthalmic Surg February 1991; 22(2): 102—8. s for performing corneal
transplants are described in, for example, US. Pat. No. 5,755,785, and in Eye 1995; 9
(Pt 6 Su):6—12; Curr Opin Opthalmol August 1992; 3 (4): 473—81; Ophthalmic Surg
Lasers April 1998; 29 (4): 305—8; Ophthalmology April 2000; 107 (4): 719-24; and Jpn
J Ophthalmol November—December 1999; 43(6): 502—8. If mainly paracrine s are
to be ed, cells may also be delivered and maintained in the eye encapsulated within
a semi—permeable ner, which will also decrease re of the cells to the host
immune system (Neurotech USA CNTF delivery system; PNAS March 7, 2006 vol.
) 3896—3901).
In accordance with one embodiment, transplantation is performed via pars plana
Vitrectomy surgery followed by delivery of the cells through a small retinal opening into
the sub—retinal space or by direct injection. Alternatively, cells may be delivered into the
subretinal space via a trans—scleral, choroidal approach. In addition, direct trans—
scleral injection into the vitreal space or delivery to the anterior retinal periphery in
proximity to the ciliary body can be performed.
The RPE cells may be transplanted in various forms. For example, the RPE cells
may be introduced into the target site in the form of cell suspension, or adhered onto a
matrix, extracellular matrix or substrate such as a biodegradable polymer or a
combination. The RPE cells may also be lanted together ansplantation) with
other retinal cells, such as with photoreceptors.
Thus, the invention also pertains to pharmaceutical compositions of RPE cells
described herein. The composition is preferably such suitable for transplantation into
the eye. Thus, for example, the RPE cells may be formulated in an intraocular irrigating
solution such as BSS plusTM.
It is expected that during the life of a patent maturing from this application many
relevant technologies will be developed for the generation of RPE cells, and the term
RPE cells is intended to include all such new technologies a priori.
As used herein the term “about” refers to i- 10 %.
The terms "comprises", "comprising", "includes", "including", g” and
their conjugates mean "including but not limited to".
The term “consisting of" means “including and d to”.
The term "consisting ially of“ means that the composition, method or
structure may include additional ingredients, steps and/or parts, but only if the
onal ingredients, steps and/or parts do not materially alter the basic and novel
characteristics of the claimed composition, method or structure.
As used herein, the singular form ll H Y
a ‘an” and "the" include plural nces
unless the context clearly dictates otherwise. For example, the term "a compound" or "at
least one compound" may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of this invention may be
presented in a range format. It should be understood that the description in range format
is merely for ience and brevity and should not be construed as an ble
limitation on the scope of the invention. Accordingly, the ption of a range should
be considered to have specifically disclosed all the possible subranges as well as
individual numerical values within that range. For example, description of a range such
as from 1 to 6 should be considered to have specifically disclosed subranges such as
from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as
individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies
less of the breadth of the range.
As used herein, the term d" refers to manners, means, techniques and
procedures for lishing a given task including, but not limited to, those manners,
means, techniques and procedures either known to, or readily developed from known
manners, means, techniques and procedures by practitioners of the chemical,
pharmacological, ical, biochemical and medical arts.
As used herein, the term “treating” includes abrogating, substantially inhibiting,
slowing or reversing the progression of a condition, substantially rating clinical
or aesthetical symptoms of a condition or substantially preventing the appearance of
clinical or aesthetical symptoms of a condition.
It is iated that certain features of the invention, which are, for clarity,
described in the context of separate embodiments, may also be provided in combination
in a single embodiment. Conversely, various features of the invention, which are, for
brevity, bed in the t of a single embodiment, may also be provided
separately or in any suitable subcombination or as le in any other described
embodiment of the ion. Certain features described in the context of various
embodiments are not to be considered essential features of those embodiments, unless
the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated
hereinabove and as d in the claims section below find experimental support in the
following examples.
EXAMPLES
Reference is now made to the following es, which er with the
above descriptions illustrate some embodiments of the invention in a non limiting
fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized
in the present invention include molecular, biochemical, microbiological and
recombinant DNA techniques. Such techniques are thoroughly explained in the
literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et
al., (1989); "Current Protocols in Molecular Biology" Volumes I—III Ausubel, R. M., ed.
(1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons,
ore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John
Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific
American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory
Manual Series", Vols. 1—4, Cold Spring Harbor Laboratory Press, New York ;
methodologies as set forth in US. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659
and 5,272,057; "Cell Biology: A Laboratory ok", Volumes I—III Cellis, J. E., ed.
(1994); "Culture of Animal Cells — A Manual of Basic Technique" by Freshney, Wiley—
Liss, N. Y. (1994), Third n; "Current Protocols in Immunology" Volumes I—III
Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th
Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected
Methods in ar Immunology", W. H. Freeman and Co., New York ;
available immunoassays are extensively described in the patent and ific literature,
see, for e, US Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987;
517; 3,879,262; 3,901,654; 3,935,074; 533; 3,996,345; 4,034,074;
4,098,876; 4,879,219; 5,011,771 and 5,281,521; nucleotide Synthesis" Gait, M.
J., ed. (1984); “Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds.
(1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984);
"Animal Cell Culture" Freshney, R. 1., ed. (1986); "Immobilized Cells and Enzymes"
IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and
"Methods in Enzymology" Vol. 1—317, ic Press; "PCR Protocols: A Guide To
Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al.,
"Strategies for Protein Purification and Characterization — A Laboratory Course
" CSHL Press (1996); all of which are orated by reference as if fully set
forth herein. Other l references are provided throughout this nt. The
procedures therein are ed to be well known in the art and are provided for the
convenience of the reader. All the information contained therein is incorporated herein
by reference.
EXAMPLE 1
Qualification 0fthe CRALBP/PM’EL I 7 double ng FACS method
The aim of this study was to qualify the CRALBP/PMEL 17 double staining
FACS method. by demonstrating the methods accuracy and precision in a minimum of 6
independent spiking assays over at least 3 testing days. The assay qualification was
performed using OpRegen® batch 5C as the positive control cells and HAD—C 102-
hESCs, as the negative control cells. A, calibration curve of known quantities of RPE
(OpRegenCFD 5C) spiked into hESCs was used for testing the accuracy and precision at
different spiking points. The expected cy and precision were up to 25% at all
points.
Staining Protocol: Negative Control hlESC cells taken from a cryopreserved
hESC hank (HAD~C l02 p48 4.5.2014) were thawed in tem (containing BSA)
according to sponsor protocols. Positive Control RPE cell stock: OpRegen® batch 5C
cells (reference line) were thawed into in 20%HS—DMEM according to sponsor
protocols. Thawed OpRegen® 5C and HAD—C102 hESC were spun down, re—
ded in l, nil PBS (9), filtered h a 35 uM cell strainer and counted with
Trypan Blue. The cell concentration was adjusted to 0.73x106 «106' cells."ml in PBS (—). 1
nlinil FVS450 was added to each cell suspension followed by vortexing and incubation
for 6 minutes at 37 3C. FVS450 was washed with 0.1% BSA, and re—suspended in 0.1%
BSA—Pc—block (5 min at RT) to block all Fc—epitopes on the cells. Cells were then
washed with PBS (—) and fixed in 80% Methanol (5 min at 4°C). Fixed cells were
washed once with PBS (—), once with 0.1% PBS—T, and permeabilized with 0.1% PBS—T
(20 minutes at RT). Permeabilization solution. was replaced with 10% Normal goat
serum (NGS) Blocking Solution (2009000 cells/50 ill) for at least 30 minutes {max one
hour) at. RT. During incubation time quality sample tubes (QSs) were prepared and at.
the end of blocking, cells were divided and lininunostained. Cells were incubated with
y antibodies for 30 minutes followed by 3 washes with 0.1% PBS—T and 30 min
incubation with secondary antibodies and 3 washes with 0.1% PBS—T.
Negative and positive control cells were stained with the viability stain FVS450,
fixed, blocked and bilized. A calibration curve of known quantities of positive
control RPE (QpRegenQ‘) 5C) cells in negative control hESCs, at 4 concentrations (25%“,
50%, 75%, and 95% RPE in thSC), was then generated based on the Trypan Blue
viability cell count of each population. Negative and positive control cells and the
mixed tions were noslained with primary monoclonal antibodies specific to
the RPE s CRALBP and Plv’llila 17, followed by staining with d
secondary antibodies (anti-niouse—FITC and anti—rabbit-Alexa Fluor 647;, respectively).
d cells were FACS ed to measure the percent viable single cell gated
CRALBP~s~PMELl7+ cells,
RESULTS
Accuracy: Accuracy of the assay was determined from test results of 4 levels of
spiked RPEs (25%, 5.0%, 75% and 95%). The accuracy of the RPE stock (OpRegen®
5C) was determined with respect to it being ially 100% RPE cells. Each level
values were analyzed by six independent runs/detenninations.
The 50% concentration level was considered to be the lower limit of quantitation
with an expected accuracy of up to 25% (50% level ranged from —8,4l to 2014; 75%
and 99.5% levels ranged from 6.32 to 6.88).
These results meet the expected outcomes for relative bias of up to 25%;, and
indicate that the assay is accurate for determination of CRALBP+PMELl7+ double
positive cells in concentrations ranging from 50—995%. Since OpRegen® 5C yields
99.5% CRAl_,BP+PMELl,'7+ double positive RPE cells, a relative bias of less than 25%
for a result >99.5% cannot be assured.
W0 2016/108239 2015/051269
Table .1
Run Assigned Concentration (%) Measured Concentration (%) Relative Bias (%)
.88 - 16.48
31.61 26.44
32.20 28.80
32.01 28.04
.71 2.84
26.87 7.48
45.93 —8. 14
60.08 20.16
56.87 13.74
58.51 17.02
50.56 1.12
49.52 -0.96
71.01 -5.32
79.64 6.19
78.41 4.55
80.16 6.88
73.85 -1.53
72.94 -2.75
93.94 -1 . 12
96.14 1.20
95.11 0.12
95.59 1.01
93.81 -1.25
93.70 -1.37
98.79 —1.21
99.69 -0.31
99.62 -0.38
100%
99.59 -0.41
99.60 -0.40
99.48 -0.52
Intermediate Precision: The intermediate precision of the assay was determined
from s of 6 assays carried out by one operator. In each assay the percent single
viable RPEs was determined and from that. the %CY was calculated. Table 2
summarizes the test results. As shown, %CY for all concentration levels was below
% and can be measured with adequate precision. %CY for the concentration levels
%., 50%., 75%. 95% and l,()()% 'RPEs, were 16.14%, 10.61%, 5.10%, 1.l§7%, and
0.34%., respectively. These results meet the expected values for precision. The ed
percent RPES is within 20% of the expected value at all concentrations. These results
indicate that the assay is e for determination of RPES in concentrations ranging
from 25~99.5%.
Table .2
Assigned Concentration (%) Run Measured Concentration (%RPE)
—Mean %RPE
—%CV
-Ln Mean %RPE
-L11 Mean %RPE
WO 08239
l 98.79
2 99.69
3 99.62
4 99.59
99.60
99.48
Mean %RPE 99.46
SD 0.34
%CV 0.34
Repeatability: Sample repeatability was tested in 3 runs {#2, #3 and #4) in
which duplicate OpRegen® SC samples were stained and acquired side by side. The
results confirmed that sample identity obtained within an experiment is able and
consistent across samples.
Linearity/range: As shown in Figure l, linearity was measured using data that
were found to be both accurate and precise. The coefficient of regression between the
target (spiked) and ed results across the tested assay range (5095-10093) was
found to be 0.99, Thus, the range of the method which demonstrates acceptable
accuracy and precision and ity is the range between 50% and 99.5% RPE cells,
which covers the expected range of tested samples.
Positive control cells: The provisional level of CRALBP/PMEL17 double
positive cells was set at equal to or r than 95 %.
Negative control cells: The provisional level of CRALBP/PMEL17 double
positive cells for hESCs was set at equal to or less than 2 %.
Stability: The results show that stained samples are stable at 4°C also after one
and 4 days and accuracy is kept within expected acceptance ia therefore the data
acquisition can be performed within 96 hours of sample preparation.
Conclusion
The results presented herein indicate that the disclosed method is qualified and
suitable for its intended use of in vitro determination of RPE purity in OpRegen® final
product and at different stages along the production process of ()pRegent’E, with
Accuracy of Relative Bias ot"< 25% and precision of QECV < 20% in the range of 50%—
99.5% RPE cells.
EXAMPLE 2
Assessing the level of OpRegen® purity
A FACS based method for assessing the level of human retinal pigment
epithelial cells (RPE) purity as well as non-RPE cellular impurities in RPE cells was
developed. Cellular retinaldehyde—binding protein P), one of the visual cycle
ents, was bioinformatically identified as a unique marker for mature RPE cells.
Preliminary studies using CRALBP specific onal antibody have shown purity of
above 98% in RPE cells generated according to methods described herein. These s
were further supported by immunostaining for PMELl7, a melanosome marker found in
RPE. In addition, different from some RPE specific markers, CRALBP is not expressed
in melanocytes, a possible neural crest cellular contamination.
Test Sample and Controls: Human primary melanocytes (ATCC, PCS—200—013)
were used as negative control cells for CRALBP and as positive control cells for
PMELl7, type I transmembrane rotein enriched in melanosomes (melanin
granules). HADClO2—hESCs at P29 (OpRegen® parental line), were used as negative
control cells for both CRALBP and PMELl7, Clinical grade OpRegen® cells (batch
2A), and research grade OpRegen® (produced in GMP like Mock production; Mock IV
D16) were used as the tested samples. The cells were generated as described in
Example 3.
staining and FACS analysis: cells were thawed and stained using the
e Viability Stain (FVS450) (BD 562247), fixed with 80% Methanol,
stained with the primary mouse anti CRALBP (Clone B2, Abcam ab15051), or
its e control for mouse lgG2a (Abcam abl70l9l) and rabbit anti human PMELl7
(Clone EPR4864, Abcam 62) followed by secondary antibodies goat anti mouse
(Dako F0479) and goat anti rabbit (Jackson 111—606—144), respectively.
Acquisition of FACS data was performed using a validated Navios flow
cytometer (Beckman Coulter) and analysis was performed using FlowJo 7.6.
WO 08239
RESULTS
Initial FACS data using anti CRALBP onal antibody and showed that the
purity level of OpRegen® is above 98%. Melanocytes which are a le neural crest
ar contaminant were found negative for the unique RPE specific marker CRALBP
(1.7%). The parental line HADC102—hESCs were negative to CRALBP (0.2%), as
expected.
The purity level of OpRegen® stayed above 98% following double staining with
CRALBP and PMEL17 (Figure 10). Melanocytes stained positive for PMEL17, as
expected, but were negative for the double marked population (~l%). HADC102—
hESCs were negative stained for CRALBP and PMEL17 (0.07%).
EXAMPLE 3
Description ofmanufacturing process andprocess controls
OpRegen® is manufactured from the xeno-free GMP grade HAD-C 102 hESC
line grown on irradiated xeno—free GMP—grade human umbilical cord fibroblast feeders.
Clinical—grade human fibroblast feeder cell line (CRD008; MCB) and working cell
banks (WCBs) were produced under Good Manufacturing ce (GMP) and xeno—
free conditions, appropriately tested, characterized and banked. These were then used in
the derivation of clinical—grade hESC line HAD—C 102 from surplus human blastocysts
under GMP and xeno—free conditions.
At the initial phase of production hESCs are expanded on irradiated feeders as
colonies. They are then transferred to suspension culture to initiate differentiation in a
directed . Spheroid bodies (SBs) are formed and then plated as an adherent
culture under continued ed differentiation conditions towards a neural fate and
subsequently towards RPE cells. At the end of the differentiation phase non—pigmented
areas are physically excised and pigmented cells are tically collected, seeded
and expanded. Purified hESC-derived RPE cells (D8) are harvested at passage 2 and
immediately sed to the DP. Duration of the manufacturing s depends on the
hESCs growth rate (~2 months from thawing) and in total usually spans over 4-5
months.
Each step of the manufacturing process, including the in—process quality control
(QC) tests is briefly described below.
Steps 1-3: Generation of human cord fibroblast feeder Working Cell Bank
(WCB). A Vial of human cord feeder Master Cell Bank (MCB) 8—MCB) at
passage 3-4 was thawed, expanded in Dulbecco's Modified s Medium (DMEM,
SH30081.01, Hyclone) supplemented with 20% human serum (l4—498E, Lonza),
ated (Gamma cell, 220 Exel, MDS Nordion 3,500 rads) and eserved at
passages 7—8 to generate the working cell banks (WCBs). Prior to cryopreservation,
samples from the feeder cell es were tested for sterility, mycoplasma and Limulus
Amebocyte Lysate (LAL), morphology, karyotype, cell number, and ity. In
addition, post thawing, their identity to the MCB, their inability to proliferate and their
ability to support un—differentiated HAD—C102—hESC growth were confirmed. If the
WCB passed all QC testing, the bank was released for expansion of hESCs.
Production Steps 1—3 are depicted in Figure 12.
Steps 4-5: Expansion of hECSs. A single Vial of the human cord fibroblast
WCB (either CRD008-WCB8 or CRDOOS-WCB9) was thawed and plated in center well
plates d with recombinant human gelatin (RhG100—001, Fibrogen) at a
concentration of 70,000—100,000 ml/plate in DMEM (SH30081.01, Hyclone)
supplemented with 20% human serum (l4—498E, Lonza). The cells were incubated over
night at 37 °C 5% C02 to allow the fibroblasts to attach. 1—4 days later, a sample from
HAD—ClO2—hESC MCB was thawed and plated for 6—7 days at 37 OC 5% C02 on top of
the feeder cells in Nutristem "Plus" Medium (which is GMP—grade and xeno—free) that
contains the growth factors bFGF and TGF—B (05—102—1A, ical Industries, Israel).
On day 6—7 hESC culture was mechanically disrupted (using a sterile tip or a disposable
sterile stem cell tool; 14602 Swemed) and passaged into additional freshly prepared
plates containing feeder cells at a concentration of 70,000—100,000 cells/plate. This was
repeated weekly for several passages to reach the necessary amount of hESC to initiate
differentiation (Figure 13, Steps 4—5). Prior to their use, expanded HAD—C102—hESCs
were tested for sterility, asma, LAL, karyotype, and identity to the MCB. In
addition, their pluripotent morphological appearance as well as d expression of
pluripotency markers (TRA-l—60, Oct4, and alkaline phosphatase) were confirmed
(Figure 2, Step 5). Production Steps 4—5 are depicted in Figure 13.
Steps 6-13: Differentiation into RPE cells. Expanded 02—hESCs were
enzymatically treated with enase (4152, Worthington) for additional expansion in
6 cm cell culture plates (Figure 14, Step 6). ed HAD—C102—hESCs were then
used in the derivation of the OpRegen® DS.
entiation of each n® batch was initiated by mechanical transfer of
collagenase A harvested clusters of HAD—ClO2—hESCs from Step 6 culture to a feeder—
free non—adherent 6 cm Hydrocell culture dishes in the presence of Nutristem "Minus"
Medium (that does not contain the growth factors bFGF and TGF—B; 06—5102—Ol—lA
Biological Industries, Special Order) supplemented with 10 mM Nicotinamide (N—5535,
Sigma) e 14, Step 7). The plates were then cultured for up to one week under low
oxygen atmosphere (5%) conditions (37 ”C, 5% C02) to allow the generation of
spheroid bodies. Week old id bodies in suspension were then collected,
dissociated gently by pipetting, and erred to human laminin (5ll, Biolamina)—
coated 6—well plates for an additional week of growth under a low oxygen atmosphere
(5%) in the H
presence of Nutristem "Minus Medium supplemented with 10 mM
Nicotinamide (Figure 14, Step 8). The cells continued to grow under low oxygen (5%)
atmosphere for an additional up to 4 weeks; two weeks in the presence Nutristem
" Medium supplemented with 10 mM nicotinamide and 140 ng/ml Activin A (G-
l20—l4E, Peprotech) (Figure 14, Step 9), followed by up to 2 weeks in the presence of
Nutristem "Minus" Medium supplemented with only 10 mM nicotinamide (Figure 14,
Step 10). When areas of light pigmentation became apparent in s of polygonal
cells, plates were transferred back to normal oxygen (20%) atmosphere (37°C, 5% C02)
and were grown for up to 2 weeks in the presence of Nutristem "Minus" Medium with
mM Nicotinamide (Figure 14, Step 11). After up to 2 weeks, expanded nal
patches with distinctive tation were apparent within areas of non—pigmented
cells (Figure 14, Step 12) and remaining pigmented cells were detached and manually
collected following 15 minutes TrprE Select (12563—011, Invitrogen) treatment at 37
0C (Figure 14, Step 13). Production Steps 6—13 are depicted in Figure 14.
Steps 14-17: Expansion of OpRegen® cells. Pigmented cells were then
transferred to 6—well gelatin—coated plates (0.5—lx106 cells/plate; P0) for a 2—3 days of
growth in the presence of DMEM (SH30081.01, Hyclone) supplemented with 20%
human serum (l4—498E, Lonza) (Figure 15, Step 14). DMEM was then ed with
Nutristem “Minus" Medium and cells were grown for 2—3 weeks until the plate was
covered with lightly pigmented nal cells (Figure 15, Step 14). These PO cells
were then ed in n—covered flasks for an additional two passages (P1, P2).
Cells at P0 and at P1 were harvested following TrprE Select treatment at 37 °C,
washed and cultured for 2-3 days on gelatin-coated flasks in the presence of DMEM
supplemented with 20% human serum. DMEM was replaced with Nutristem "Minus"
Medium and the cells were grown for 2—3 weeks until the plate was covered with lightly
pigmented polygonal cells (Figure 15, Steps 15—16). Cells at P2 grown in T175 flasks
were then harvested following TrprE Select treatment at 37 0C, re—suspended in
DMEM supplemented with 20% human serum, pooled and counted.
A sample of growth medium from each batch was taken for sterility,
asma, and LAL testing. The cells morphology was observed and documented
(Figure 15, Step 17). Production steps 14—17 are depicted in Figure 15.
EXAMPLE 4
Process Control Points
IPC points are depicted in Figure 16. The sampling points chosen to assess
hESC impurity and RPE purity along the production process are bed below:
IPC point 1: Mechanically expanded HAD—C 102 hESCs prior to their
differentiation that have normal karyotype. This is the starting material in which the
highest level of hESCs is expected. This point was added to evaluate the maximal hESC
level prior to entiation.
IPC point 2: Collagenase expanded HAD—C 102 hESCs prior to their
differentiation. At this stage, some differentiation is expected, and thereby a reduction
in the level of cells sing Oct4 and 60 as well as in the expression level of
GDF3 and TDGF. This point was added to evaluate hESC impurity during the phase of
non—directed differentiation.
IPC point 3: Spheroid Bodies produced one week post induction of hESC
differentiation under feeder free conditions in the presence of namide. At this
earlier stage of differentiation, hESC impurity during differentiation is expected at the
maximal level and thereby this assessment is expected to give an indication for the
highest level of safety concern.
IPC point 4: Cells at the end of Activin A treatment. Activin A directs the
differentiation towards RPE cells. At this point, a major decrease in hESC impurity and
a high increase in expression of RPE markers are expected. This point was added to
monitor hESC differentiation to RPE.
IPC points 5-7: Cells at the end of the differentiation s prior and post
separation of the non—pigmented areas (IPC point 6) from the pigmented areas (IPC
point 7). IPC points 5 and 6 are expected to contain cellular ties, while sample 7
ents the product at the end of the differentiation process prior to its expansion.
Cellular contaminations found in sample 6, may be found is small quantities in sample
7, and in r quantities in the product.
IPC point 8: Pigmented cells at P0. Pigmented cells at the end of the
entiation process that were expanded for 2—3 weeks. These cells represent the
product two stages prior to the end of the production process.
IPC point 9: Pigmented cells at P1. P0 cells that were expanded for 2—3 weeks.
These cells represent the product one stage prior to the end of the production process.
IPC point 10: Pigmented cells at P2 prior to cryopreservation. P1 cells that were
expanded for 2—3 weeks are harvested and pooled. These cells represent the drug
substance (DS) prior to cryopreservation.
IPC point 11: Cryopreserved ted cells at P2. These cells represent the
drug product (DP). Throughout production, at all sampling points, cell culture medium
was collected for assessment of pigment epithelium derived factor (PEDF) secretion,
known to be ed from RPE cells.
RESULTS
Quantification of TRA60+0ct4+hESCs: The level of hESCs in the various
samples ted along the production process was determined using a highly sensitive,
robust Oct4/TRA—1—6O double staining FACS method. A week following removal of
feeders and growth factors that supports pluripotent cell growth (TGFB and bFGF), at
growth conditions that supports early neural/eye field differentiation, there were only
0.0106—2.7% TRA—l—60+Oct4+ cells (IPC point 3, Spheroid Bodies). ing on
of Activin A that promotes RPE differentiation, the level of TRA—l—60+Oct4+ cells was
further deceased to 0.00048—0.0168% (IPC point 4, end of actiVin), and at the end of
differentiation following excision of non—pigmented cells, the level of TRA—l-60+Oct4+
cells was 0.00033—0.03754% (IPC point 7, pigmented cells). At P0, two stages prior to
the end of the production process, TRA—l— 60+Oct4+ cells in levels of 0.00009—
0.00108% (below LOD—close to LLOQ) were detected (IPC point 8). The levels of
TRA60+Oct4+ cells at P1 (IPC point 9), P2 prior to cryopreservation (Drug
Substance; IPC point 10), and P2 post cryopreservation (DP; IPC point 11) were below
assay LLOQ (i.e. 0.00004-0.00047%, 0.00000—0.00016% and 0.00000-0.00020%
respectively).
Relative expression of the pluripotency hESC markers GDF3 and TDGF: The
relative expression of the pluripotency genes GDF3 and TDGF at the various IPC points
along the production s was analyzed. There was a l reduction in the
expression level of GDF3 and TDGF, which was correlated with the gradual reduction
in the s of TRA—l—60+Oct4+ cells, along the differentiation process. At the end
of P0, two stages prior to the end of the production process, P1, and P2 prior (Drug
Substance) and post (Drug t) cryopreservation, the expression levels of GDF3
and TDGF were r to the level of expression seen in the negative control
OpRegen® 5C cells.
Quantification of CRALBP+PMEL17+ cells: Assessment of
CRALBP+PMEL17+ cells for measurement of RPE purity was ed at the end of the
differentiation phase, at P0 and P2 (IPC points 8 and 11), respectively), were assessed.
As can be seen in Table 3 and in Figure 17, the level of CRALBP+PMEL17+ RPE purity
at P0 (IPC point 8), two stages prior to the end of the production process, was in the
range of 98.53—98.83%. Similar level of RPE purity was ed at P2 post
eservation (99.61—99.76%; IPC point 11) (Table 3).
Table 3
0"MCRALBP PMM‘H+ 1 + (,ellsV
IPC Point Sampling Time and Stage
n-————
DP, Drug Product. *IPC point 8 was tested post cryopreservation. Internal assay
controls of RPE cells (OpRegen® 5C, positive control) spiked into hESCs (HAD-C 102,
negative control) demonstrated accuracy error of 325%.
Confocal imaging of Bestrophin 1, MITF, and CRALBP immunostained cells
along Mock production runs 4 and 5: Cells were immunostained for the RPE markers
WO 08239
Bestrophin 1, MITF, 20-1 and CRALBP at the end of the differentiation phase (IPC
point 7), at the end of the expansion phase (IPC point 10, DS), and post
eservation (IPC point 11, DP). Manually isolated non-pigmented cells (IPC point
6) were plated for immunostaining, but during fixation were detached from the plate
and thereby could not be stained. Selected pigmented cells (IPC point 7) plated for 12
days (in mock 5 only, in parallel to cells at P0 from the ongoing production) and for 28
days were positively d for all tested RPE markers and the percent cells expressing
Bestrophin 1 and MITF were 93% and 93.3—96.5%, respectively. Similar levels of
Bestrophin 1 and MITF positive cells were detected at P0 (94.9% and 95.9%,
respectively; tested only in mock 4), P2 prior cryopreservation, Drug Substance (92.2—
92.75% and 5.5%, respectively), and P2 post cryopreservation, Drug Product
(91.1—95.7% and 83.8—94.9%, respectively; sed MITF immunostaining in mock 5
demonstrate an outlier of the randomly ed area for analysis). CRALBP (as well as
ZO-l) expression was detected in all IPC 7, 10 and 11 samples (Figure 18).
Relative expression ofthe RPE markers Bestrophin 1, CRALBP and RPE65
along Mock productions 2, 4 and 5: The relative expression of the RPE genes
phin 1, CRALBP and RPE65 at the s IPC points along the production
process was measured. There was a gradual increase in the relative expression level of
Bestrophin 1, CRALBP and RPE65 along the production process. At the end of Activin
A treatment (IPC point 4), that directs the differentiation towards RPE cells, the relative
levels of Bestrophin 1, CRALBP and RPE65 were 685, 36, and 325, respectively, fold
higher as compared to their ve levels in mechanically passaged hESCs prior to
differentiation (IPC point 1; mock 4). The relative expression levels of Bestrophin 1,
CRALBP and RPE65 reached a peak from the end of the differentiation stage (IPC
points 5) to the P1 stage (IPC point 9). At these stages the respective levels of
expression were 5,838—11,841, 9, and 5,708—8,687, fold higher as compared to
the levels in mechanically passaged hESCs prior to differentiation (IPC point 1).
Morphology assessment along Mock productions 4 and 5: Cells were analyzed
for morphology at the end of the differentiation phase (IPC point 5) for estimation of the
relative area of ted cells, and at the expansion phases P0—P2 (IPC points 8—10), to
verify confluent polygonal morphology. The relative pigmented cellular area estimated
at the end of the differentiation phase prior to excision of the non—pigmented areas (IPC
point 5), was 32.5% i 13.5% (average 1 SD, n=7 wells of a 6 well plate) in mock 4 and
60% i 13% in mock 5 (average i SD, n=7 wells of a 6 well plate) (see representative
images in Figure 11). Areas of pigmented cells were selected and expanded.
Morphology at the end of the ion phases PO (IPC point 8), Pl (IPC point 9), and
P2 (IPC point 10) demonstrated a densely packed culture with a typical polygonal—
shaped epithelial monolayer morphology (Figure 11).
PEDF secretion and potency measurement along Mock productions 4 and 5:
Pigment epithelium—derived factor (PEDF), known to be secreted from RPE cells, was
measured in the cell culture medium at various IPC points along mock productions 4
and 5. As can be seen in Table 4, very low levels of PEDF, in the range of 4—79
ng/mL/day, were secreted by hESCs (IPC points 1 and 2) and by spheroid bodies (IPC
point 3; end of the first week with Nicotinamide). At the end of Activin A treatment
(IPC point 4), that directs the differentiation s RPE cells, the level of secreted
PEDF was in the range of 682-1,038 day, 31-37 fold higher ed to the
level ed by spheroid bodies. Following incubation of cells at normal oxygen
conditions with Nicotinamide (IPC point 5), further increase (2.2—4.6 fold) in PEDF
secretion to l,482—4,746 ng/mL/day, was observed. During the expansion phase (PO—P2,
IPCs 8—10, respectively), PEDF secreted levels were in the range of 2,187—8,68l
day, peaking at PO—Pl.
Table 4: PEDF ion along mock productions 4 and 5.
IPC Sampling Time and Stage PEDF secretion (ng/mL/day)
Range
Mock 4 Mock 5
nMechanically passagcd hESCs —
l Mechanically passagcd hESCs D D
Mechanically passaged hESCs 4 D 22
Collagenase passaged hESCs —21 79 21-79
28 22-28
Cells at the end of Act1v1n A
682 1 038 682-1,038
treatment
“——7523-7951
“——zzsv-sasl
1187-1147
OpRegen® (P2); DP 2,462 3,936 2,462-3,936
ND, Not done; NA, Not able; DS, Drug Substance; DP, Drug Product.
Tight junctions generated between RPE cells enable the generation of the blood—
l barrier and a polarized PEDF and VEGF secretion. PEDF is secreted to the
apical side where it acts as an anti angiogenic and neurotropic growth factor. VEGF is
mainly secreted to the basal side, where it acts as a proangiogenic growth factor on the
choroidal endothelium. RPE polarization (barrier on and polarized PEDF and
VEGF secretion) was measured in a transwell system at the end of P0 (IPC point 8), end
of P2 prior to cryopreservation (IPC point 10), and end of P2 post eservation (IPC
point 11). As can be seen in Table 5, barrier function/trans-epithelial electrical
resistance (TEER) and polarized secretion of PEDF and VEGF were demonstrated at all
IPC points.
Table 5
Polarization
Transwell- ell-
. . . Transwell
IPC Pomt Sampling Tlme PEDF ratio at VEGF ratio
PEDF Ba 14 -TEER
and Stage y
Week 3 at Week 3
(ng/mL/day) 6521?; (Apical/Basal (Basal/Apical
) )
3,229 6.72
4,55 4.72
Polarization
Transwell- Transwell-
Transwell
IPC Point ng Time PEDF ratio at VEGF ratio
PEDF Day 14 -TEER
and Stage Week 3 at Week 3
(ng/mL/day)-‘21!2.£;
(Apical/Basal (Basal/Apical
) )
ratio:
2.54—
2.73
2:6 3693
ND, Not Done; DS, Drug Substance; DP, Drug Product. PEDF and VEGF were measured by
ELISA. PEDF day 14 was collected from the cells during their culture in a 12-well plate. Cells
were then passaged onto a transwell and ed for 6 weeks, during which TEER, and
secretion of VEGF and PEDF from the basal and apical sides of the transwell were measured
Batch Release Testing ofRPE cells produced in Mock runs 4 and 5: To verify
that n® produced in mock runs 4 and 5, is comparable to GMP produced
OpRegen®, iated OpRegen® batch release testing was carried out that included
morphology testing at the end of P2 prior to cryopreservation (IPC point 10, DS), and
Viability, total cell number/cryovial, identity ssion of Bestrophin l and MITF),
hESC impurity, and karyotyping at the end of P2 post cryopreservation (IPC point 11,
DP). OpRegen® produced in Mock runs 4 and 5 passed batch release criteria.
OpRegen® produced in mock run 2 was not eserved, and thereby could not be
tested.
CONCLUSION
Three mock production runs (mock runs 2, 4, and 5) were carried out under
research grade conditions using the same GMP—production methods, XCI’IO-fI'CC GMP—
grade cells (HAD-C 102 hESCs grown on irradiated CRD008 feeders), xeno-free GMP
grade reagents and GMP grade lab—ware that were used in the GMP tion of the
clinical batches. Mock productions 2, 4 and 5 aimed at assessing the level of hESC
impurity along the production and Mock productions 4 and 5, also aimed at identifying
important in process quality ls.
Using a qualified TRA—l-60/Oct4 double ng FACS method (LOD
0.0004%, 1/250,000 and LLOQ of 0.001%, 1/ 100,000) and a qualified flow cytometer,
hESC impurity in level below assay LOD was observed at the end of the differentiation
phase, in the negatively selected pigmented cells, three stages prior to the end of Mock
production s. In mock runs 2 and 4, performed prior to assay ication using
core facility flow cytometer, the level of hESC impurity was below assay LOD two
stages prior to the end of the production s. In support with this data, quantitative
RT—PCR analysis demonstrated down regulated expression of the pluripotent hESC
genes GDF3 and TDGF to levels similar to the negative control (OpRegen® 5C cells)
two stages prior to the end of the production process.
Identity g med three stages prior to the end of production (isolation
of pigmented cells) demonstrated sion of Bestrophin 1 and MITF by 93% and
96.5% of the immunostained cells, tively, as well as expression of CRALBP and
ZO-l (not quantified). RPE purity testing performed one stage later (i.e. P0, 2 stages
prior to the end of the production process), following one expansion cycle of the
negatively selected pigmented cells, showed that > 98.5% of the cells were
CRALBP+PMEL17+ double positive by FACS. Similar level of RPE purity (i.e. >
99.6%) was also detected in the drug product. These results were supported by
morphology testing demonstrating typical polygonal shaped epithelial monolayer
morphology and by quantitative RT—PCR analysis demonstrating upregulated
expression of the RPE genes Bestrophin l, CRALBP, and RPE65 to levels similar to the
positive control (OpRegen® 5C cells).
PEDF, known to be secreted from RPE cells, was measured in the cell culture
medium at various stages along the production process of mock runs 4 and 5. At the end
of the n A treatment (IPC point 4), previously shown by Idelson et al. 2009) to
direct the differentiation towards RPE cells, the level of secreted PEDF was highly
increased (31 fold in mock 4 and 37 fold in mock 5) relative to the us production
step (induction of spheroid bodies). PEDF secretion levels continued to increase and
peaked at P0—P1 (1.7—5.8 fold increase relative to the levels after Activin A).
Assessment of the relative area of pigmented cells at the end of the differentiation
process (IPC point 5) was fied as r important quality control e for
assessment of RPE differentiation. Using this measure, a 2 fold difference in the yield
of pigmented cells in mock 4 and 5 runs (32.5% in mock 4 and 60% in mock 5) was
observed, that was correlated with a similar difference seen in PEDF secretion at this
stage (1,482 ng/ml/day in mock 4 and 4,746 ng/ml/day in mock 5).
In conclusion, no TRA—1—60+Oct4+ hESC impurity observed as early as 3 stages
prior to the end of the production process. This was correlated with low expression
levels of GDF3 and TDGF, high expression levels of Bestrophin 1, CRALBP and
RPE65, and high levels of Bestrophin 1 and MITF single positive cells, as well as high
CRALBP+PMEL17+ double positive cells (tested one stage later). Important safety and
efficacy IPCs were fied at critical production stages.
EXAMPLE 5
Efficacy Assessment
Experimental set-up: The present inventors examined whether subretinal
transplantation of the RPE cells generated as described in Example 4 could delay the
progression of RDD in the Royal College of Surgeons (RCS) rat model.
,000, 100,000 or 200,000 RPE cells were transplanted into the subretinal
space of one eye of RCS rats on post—natal day (P)21—23 (prior to photoreceptor death
onset); BSS+(Alcon) treated and naive untreated animals served as controls. Groups
were separated into 4 survival ages: post—natal day P60, P100, P150 and P200. Fundus
photography was used to identify bleb formation and monitor injection y.
Funduscopy was also performed at P60, P100, P150 and P200. Optomotor tracking was
used to measure Visual acuity of all animals at all time points (P60, P100, P150, P200).
Focal and full field ERGs were ed in all study groups at P60 and P100. At
the assigned sacrifice date for each , both eyes were removed, fixed in 4%
paraformaldehyde, cryopreserved, ed in Optimum g Temperature
compound (OCT) and cryosectioned. Cresyl Violet staining was used to fy and
ate photoreceptor structural rescue. Immunofluorescent ng (IF) was used to
identify transplanted cells, assess their fate, their state of proliferation, and their ability
to phagocytose photoreceptor outer segments. In addition immunofluorescene was used
in measurement of host cones rescue.
The study design is summarized in Table 6 herein below.
Table 6
TIME OF SACRIFICE POST
INJECTION
TREATMENT GROUPS
Number of Mice (male and female)
# at Study Initiation
III-MI
[Mm IIII
I’ PE High Dose IIII
MATERIALS AND METHODS
Cell counts: Cells were counted before being aliquoted into appropriate dosage
concentrations. Pre—injection cell viability for all injection time points averaged 94.0%i
0.03. Post ion cell viability ed 92.4%i0.02.
Surgery: A small incision was made through the conjunctiva and sclera using
incrementally smaller gauge s: 18, 22, 25, and 30. A lateral margin puncture of
the cornea was used to reduce cular pressure, to reduced egress of the injected
cells. The glass e was then inserted into the subretinal space and 2 ul of
suspension injected. The sclerotomy was then sutured closed. Successful injection of the
cells or buffer alone (BSS+) was med first by manual visualization of a subretinal
bleb, which was subsequently raphed through the use of a fundus camera
(Micron III).
Optokinetic tracking thresholds: Optokinetic tracking thresholds were
measured and recorded in a blinded fashion. Repeated measures ANOVA or one—way
ANOVA with Fisher’s LSD post hoc analysis was used to analyze OKT data.
Electroretinagram (ERG): Two forms of ERGs were ed: an exploratory
form of focal ERG where a small spot of light is used to stimulate a localized area of
retina, and a standard style of full field ERG where the entire visual field is stimulated.
Histology and Immunohistochemistry: Both eyes from each animal were
harvested, fixed, cryoprotected, embedded, and . Frozen blocks were
cryosectioned at 12 um. Approximately 60 slides containing 4 sections per slide were
obtained.
Cresyl : Cresyl violet stained sections were examined for: 1) injection site
and suture, 2) evidence of photoreceptor rescue, 3) evidence of transplanted cells, 4)
untoward pathology. For each slide, maximum outer nuclear layer thickness was also
recorded for quantification of rescue.
fluorescence (IF): RPE cell treated eye slides ed for IF were
chosen from cresyl violet stained sections that contained cells in the subretinal space
tent with the size and morphology of the lanted human cells. In on,
protection of the host ONL was used as a secondary criterion. All IF ng was
performed as dual stains with DAPI serving as a background nuclear stain. At least one
slide from every cell treated animal was used for each run.
Run #1 was performed using rabbit onal Anti—Melanoma gplOO
(PMEL17, Clone EPR4864; human specific, Abcam cat#ab137062) co—stained with
mouse monoclonal Anti—Nuclei Marker (HuNu, Clone 3El.3, Millipore, cat#MAB4383)
for detecting human RPE and non—RPE cells.
Run #2 was performed using rabbit monoclonal Anti—Ki67 (Ki67; Clone
EPR3610, human specific, Abcam, cat#ab92742) and uclei Marker for detecting
human proliferating cells.
Run #3 was performed using rabbit polyclonal at Cone Arrestin (Millipore
cat#ab15282) to evaluate sections for cone counting (see Section 6.8.3). In addition,
selected slides were stained using mouse monoclonal Anti Rhodopsin (Clone Rho 1D4,
Millipore, MAB5356) in combination with PMEL17 to identify transplanted human
cells containing host rhodopsin/outersegments as a measure of their phagocytic activity.
Cone Counting: Confocal z-stack images were acquired from sections of retina
obtained from all cell transplanted eyes and from age—matched saline injected controls.
ns from cell injected eyes were chosen in the area of photoreceptor rescue as
defined using the previously evaluated cresyl violet stained sections. Cones were
counted by 3 observers in a blinded fashion. The three counts were then averaged and
counts compared between dosage groups and age.
Rhodopsin ingestion: A potential mechanism of rescue employed by the
transplanted cells is to ingest photoreceptor outer segments and shed debris. Removal of
the debris zone reduces the toxic stress on the photoreceptors and thus, aids in
sustaining photoreceptor survival. Here, the present inventors selected specific animals
for evaluation of sin ingestion by the RPE cells based on the cell survival and
photoreceptor protection indices. This evaluation was performed using
immunofluorescence.
RESULTS
Fundus Imaging: Fundus images ted at necropsy of cell treated eyes
revealed hyper and hypo—pigmented areas of the retina that corresponded to the location
where subretinal blebs were formed during surgery; the location at which cells were
deposited in the subretinal space (Figures l9A—C). These patchy areas were not evident
in BSS+ injected or non—injected eyes.
Optokinetic ng thresholds: OKT thresholds were rescued in all cell
treated groups at all ages (Figure 20). Cell—treated groups outperformed un—operated or
saline injected eyes at all ages. There was a significant dose dependent effect between
the low dose (25K) and the two larger doses (100K (p<0.0001) and 200K (p<0.0001)),
especially at the later ages, but no clear benefit to the OKT from the high dose (200K)
over the intermediate (100K) dose was observed 646). While OKT thresholds
were rescued in all cell treated groups, the te visual acuity values slowly declined
with time. Untreated and saline injected animals’ OKT thresholds continue to decline
over the course of the study. BSS+ injected eyes were not different from naive untreated
group (p=0.6068) and untreated fellow eyes.
Focal ERG: Focal ERG’s were measured in all (n=252) mental rats at
~P60. Individual animals treated with RPE cells performed well and significantly
formed controls, as rated in Figure 21A.
Fullfield ERG: Full field ERG’s were measured from 125 RCS rats at P60 and
from 63 RCS rats at P100. Individual animals treated with RPE cells med well
and icantly outperformed controls, as illustrated in Figure 21B.
Cresyl Violet staining: An ary photomontage of a cresyl violet stained
section is presented in Figure 22A. Representative images from BSS+ injected and cell
treated s from multiple groups) eyes are presented in Figure 22B.
Outer nuclear layer thickness (ONL) was measured as the primary indicator of
photoreceptor rescue. Data was recorded as maximum number of photoreceptor nuclei
present in each dose group across ages (Figure 23). Cell treated groups had significantly
higher ONL thickness at P60, P100 and P150 (All p<0.0001) than BSS+ d eyes. In
terms of percentage of animals with evidence of photoreceptor rescue, 76—92% of
s at P60, 80—90% at P100, 72—86% at P150, and 0—18% at P200 had evidence of
photoreceptor.
Immunofluorescence: Transplanted RPE cells were positively identified by
immunofluorescence in s of each survival age (Figure 24), however, the number
of animals with identified cells decreased as age increased. Repeat staining of additional
slides in animals that did not originally reveal transplanted cells resulted in additional
s identified with positive cells, but not in all cases.
Despite not g transplanted cells in all s by IF is, ONL
thickness measurement results indicated 70-90% of cell treated animals had significant
photoreceptor , confirmed with OKT rescue, suggesting that most treated eyes
contained transplanted cells at some point. The proliferation marker Ki67 was used to
identify proliferating human cells. Ki67 positive human cells were not observed (Figure
24).
Cone Counting: Cone counts in animals that received cell transplants were
significantly better than control eyes (Figure 25; p=<0.0001 for each comparison). In
general, there was no difference n cone counts across the low, middle and high
dosage of cells. A representative image from each age is presented in Figure 24.
Rhodopsin ingestion: In each case tested (n26), fluorescently labeled rhodopsin
was observed within the transplanted RPE cells (Figures 26A—J). This ms the
transplanted cells do ingest outer segment debris post lantation.
Conclusion
When transplanted into the subretinal space of RCS rats, RPE cells rescued
Visual acuity in the RC8 rat over that of controls at all ages tested. ERG responses were
protected when the graft was large enough or in an area of retina accessible for
assessment. Rod and cone photoreceptors were rescued in the area of the grafts for up to
180 days post—transplantation. Collectively, this data demonstrates that OpRegen®
maintain the functional and structural integrity of the host retina for ed periods.
Thus, OpRegen® hold significant potential for the treatment of human RPE cell
disorders such as RP and AMD.
EXAMPLE 6
Stability ofRPE cells
Short-term stability
Formulated RPE cells (generated as described in Example 4) in BSS plus were
prepared at a final volume of 600—1000 ul per vial. Short term stability was tested at
time points 0, 4, 8 and 24 hours. Cells were found stable at all time points.
RPE cell viability and cell tration were stable at the 8 hour incubation
time point for all dose formulations; percent average ity (i SD) for the ing
concentrations:
- Low tration (70 x103 per 100 ul BSS plus) changed from 93% i 5 at
time point 0 hours to 91 % i 1 at time point 8 hours, a non-significant decrease.
- High concentration (70 x103 per 100 ul BSS plus) changed from 92% i 3 at
time point 0 hours to 91 % i 2 at time point 8 hours, a non—significant decrease.
For the medium concentration (250 x103 per 100 pl BSS plus) that was tested
there was no significant change throughout the time points.
The overall range for all time points and formulated doses was between 88% —
97% from time point 0 hours to 8 hours, when ing all results for time point 0
hours (93% i 3) and time point 8 hours (91 % i 1) a decrease of 2% was found.
No significant changes in the cell concentration were observed, in either time
points or formulated doses. Cell concentration did not change in all 3 studies other than
a small decrease seen in one batch in the high dose (2%).
Appearance of the different dose formulations did not change throughout the
tested time points; cell suspension was free of foreign particles and non—dissociated
aggregates.
Identity and purity of each formulated RPE cell dose at all tested time points
were stable up to 24 hours and were within the batch e criteria. At 8 hours (for all
formulated RPE cell doses), the level of MITF and Bestrophin positive cells was in the
range of 86—97% and 90—94%, respectively, and the level of +PMEL17+
double positive cells was in the range of 98.35—99.64%.
WO 08239 2015/051269
Formulated RPE cell doses maintained their potency in all tested time points (4,
8, 24 hours), both secreting high levels of PEDF and forming a polarized RPE
monolayer with a polarized secretion of PEDF predominantly to the apical side and
VEGF to the basal side. Results for the tested time points 8 hours: TEER was in the
range of 376 — 724 ohms, PEDF apical to basal ratio in the range of 2.77 - 5.70 and
VEGF basal to apical ratio in the range of 2.04 — 3.88.
Sterility was kept at all incubation time points for all cell dose formulations.
These results support OpRegen® cell stability in final formulation at all clinical
doses for at least 8 hours when kept at 2—8°C. A safety margin of up to 24 hours exists
based on l data collected (identity, sterility, and medium dose potency).
Results of the short term stability assay are summarized in Table 7 below.
Table 7
MID DOSE HIGHDOSE
ANCE DOSE
250,000 700,000
CRITERIA 70,000
cells/100 ml cells/100 ml
cells/100 ml
Cell Viability 2 70% 91 i1 (11:3) 92 (11:1) 91 i 1.5 (11:3)
i 40%from initial 91.3 i 30
Cell Dose 103 (n—1)_ 104 i 5.7 (n—3)_
dose (11:3)
MITF Positive Cells 2 80% 90 (n:2) 93 (n=1) 96 (n:2)
phin 1 Positive Cells 2 80% 94 (n:2) 92 (n=l) 92 (11:2)
CRALBP+PMEL17+ Cells 2 95% 9951:3215 99.5 (11:1) 99 i 0.65 (11:3)
Barrier Function, TER ((2) 605 (n:2) 724 (n=1) 410 (n:2)
Polarized PEDF Secretion
3501—1)_ 4'5 ("—2)_
(Apical/Basal) For Information Only
Polarized VEGF Secretion
2’2 ("—1)_ 2'3 ("—2)_
(Basal/Apical)
Sterility USP<71> Negative Negative
No foreign particles
Appearance and/or non-dissociated Pass Pass Pass
aggregates
Long-term stability: Three s of RPE cells were frozen in vapor phase
liquid nitrogen. Testing of the long—term stability in eservation started after the
ng date. Results provided are following three years of freezing. The following
parameters are being tested: Viability, cell number, RPE identity (% Bestrophin l and %
MITF ve cells), RPE purity (FACS% CRALBP+PMEL17+ RPE cells), potency
(polarization and PEDF secretion), karyotype analysis and sterility. At each time point,
the ed number of Vials are thawed and the cells are ed for the assays as
bed herein.
Results of the long term stability assay are summarized in Table 8 below.
Table 8
TEST 0-3 Months 19-21 Months 34-36 Months
Cell Viability 86 i 2 (n=3) 87 i- 4 (n=5) 89 i- 2 (n=6)
Total Cells/Vial 1.44 i 0.13 (n=3) 1.13 i 0.2 (n=5) 1.13 i 0.2 (n=6)
—--86(11-2)Identity: MITF Positive _
Bestrophin 1
. CRALBP PMEL17- + +
99.8 NA 994
Cells
Pgtency: Barner Function, TER 616 368 396 i 200 (n=3)
Polarized PEDF Secretion
3.93 3.86 3.05 i 0.04 (n—3)_
(Apical/Basal)
Polarized VEGF Secretion
Safety: Karyotyping
ity USP<71>
RESULTS
Viability, total cell number/vial and RPE identity were ined throughout
the three year period. In addition, as indicated, data demonstrated potency and purity at
levels similar to the ones collected prior to preservation.
A normal karyotype was observed 4 years post cryopreservation. This indicates
that long—terrn storage in vapor phase thus far did not have any deleterious effects on
RPE genomic stability.
Sample sterility was demonstrated by testing for the absence of bacterial/fungal
growth in all clinical batches at 3 months. Another batch was tested negative 4 years
post cryopreservation. Based on these uniformly acceptable stability results, covering a
period of three years of ity testing thus far, it is concluded that the RPE cellular
product is stable for at least three years when stored at a temperature 3 —180°C in the
vapor phase of liquid nitrogen.
EXAMPLE 7
Safety and Biodistribution
The objectives of the study were to evaluate survival, biodistribution, and safety
of RPE cells ated as described in Example 4) following subretinal stration
in male and female ID mice over a 6-month study duration.
NOD—SCID mice (NOD.CBl7—Prkdcscid), 5—6 weeks of age at the time of
injection, were injected with either BSS Plus (Vehicle l) or with two doses of
RPE cells: 50x103 cells or 100x103 cells (maximal feasible dose), suspended in l uL
BSS Plus. RPE was administered into the subretina via the transvitreal route (the
proposed clinical route of stration) using a 33G Hamilton needle. A single dose
of 50x103 cells or 100x103 cells was ed to one eye, while the fellow eye served as
an internal control. Each dosing session contained mice (males and females) from each
group. Mice included in the study after pretest, were randomly assigned to the various
test . Two randomizations were performed. A measured value randomization
procedure, by weight, was used for placement into treatment groups prior to vehicle/test
article administration. Following administration, s suitable for use on study were
transferred to the target study using a sequential randomization for placement into the
final treatment groups. Mice with ocular abnormalities, al clinical observations
or weighing less than 16 gram at pretest and mice undergoing non—successful subretinal
RPE injection were excluded from the study.
Study Measurements: Assessment of RPE safety in this study was based on
animal mortality, clinical observations, body weight, ophthalmologic examinations,
clinical pathology (hematology and blood chemistry), gross ogical macroscopic
evaluations, organ weights ute and relative to body and brain weights),
histopathological evaluation of eyes and various . Assessment of survival and
biodistribution of RPE was performed by histopathological and fluorescence
immunostaining evaluations of eyes and various organs and qPCR analysis. The
following measurements were performed:
- Clinical observation;
- Body weight;
- Ophthalmologic examinations (including macroscopic and biomicroscopic
examinations);
WO 08239
- Surgical microscopic examination of subretinal injection y using the LEICA
M80 Stereo microscope (funduscopy);
0 Complete blood count and blood chemistry;
- Necropsy and gross pathology;
- Organ weight (absolute and relative to body and brain weights);
- Collection, fixation, and paraffin blocking of d and non—treated lateral eyes
including optic nerve;
- d H&E histopathology of eyes and tissues (sternum bone with bone marrow,
brain, heart, kidneys, liver, lung, mandibular lymph nodes, spinal cord, spleen, thymus,
masses and gross lesions);
- Blinded semi quantitation of pigmented cells in H&E stained slides;
- Blinded immunostaining of selected slides nt to a representative H&E slide
demonstrating pigmented cell graft in the eye for a human marker (human nuclei) plus
an RPE marker (human PMEL17) and assessment of human RPE and non-RPE cells,
human marker (human nuclei) plus a proliferation marker (human Ki67) and assessment
of human and non-human proliferating cells, and RPE marker ) plus
proliferation marker (human Ki67) and assessment of RPE and non—RPE human
proliferating cells;
- Blinded immunostaining of selected slides adjacent to a representative H&E slide
demonstrating teratoma, tumor, al cells and lesions for a human marker (human
nuclei) to exclude human origin;
- Collection and extraction of genomic DNA from blood, bone marrow (collected from
femurs), brain, left and right eyes with optic nerves, heart, left and right kidneys, liver,
lung, mandibular lymph nodes, ovaries, skeletal biceps femoris muscle, spinal cord,
spleen, testes, and thymus and qPCR analysis of human beta globin;
- H&E histopathology on tissues (other than the above) found positive for human beta
globin in animals from the same group and time point.
RESULTS
There were no RPE—related toxicologic findings in the e examinations
which included detailed clinical observation, body weight, ophthalmologic examination
and clinical ogy sed of hematology and serum clinical chemistry. The
WO 08239
ation of “Eye discolored, dark” in the left eye with an albino background was
found in mice treated with pigmented RPE cells at both dose levels in the detailed
clinical observation and ophthalmologic examination. lmologic examination of
the surviving animals indicated that this ation consisted of treal, darkly
pigmented foci. The pigmented foci were distributed randomly along a line extending
from the temporal ior lens capsule to the nasal retinal surface. These foci were
reted to be RPE cells ng from the injection a upon its removal from
the eye following injection, as supported by the vitreal reflux seen during injection or
RPE cells leaking into the vitreous humor subsequent to subretinal implantation.
All of the ocular lesions observed on this study were considered to arise
secondary to anesthesia, the surgical injection procedure, or incidentally as age—related
changes. The finding of multiple pigmented foci within the vitreous humor suggests that
RPE cells may be viable within the vitreous body. The presence of pigmented cells in
the vitreous body in some of the RPE-treated animals was confirmed at the microscopic
level.
In terms of biodistribution as evaluated by qPCR using a set of human beta-
globin gene probe/primers, at the 2-week, 2—month, and 6—month intervals, the left eyes
treated with 100x103 OpRegen® cells were positive for RPE DNA in 8/12, 11/12, and
16/16 animals with group mean levels at 38, 47 and 249 copies/ug total eye DNA,
respectively, ting a trend of increase over time. There was no significant
difference between males and females. In these animals, RPE DNA was not detected in
the untreated right eyes and all the non—eye tissues, which included blood, femoral bone
marrow, brain, heart, kidneys, liver, lung, mandibular lymph nodes, ovaries, skeletal
biceps femoris muscle, spinal cord, spleen, testes, and thymus, except for the spinal
cord (27 copies/ug DNA) from one 2—week male animal and the skeletal muscle (16
copies/ug DNA) and spinal cord (below level of qualification) from one 2—week female
animal (probably due to inadvertent contamination by ous human DNA during
DNA tion from these tissues).
RPE-related macroscopic changes were limited to black discoloration or black
foci in the left eye of a few animals at the 2 and 6—month intervals, consistent with in—
life clinical observation and/or ophthalmologic examination. These changes correlated
to pigmented cells and were not considered adverse as determined by microscopic
WO 08239
examination of surviving animals in the high—dose group and of the animals euthanized
in extremis and found dead in both dose groups. Pigmented cells were present in the
treated left eye in nearly all of the surviving mice examined at each time point in the
high dose group (at the subretinal space in 11/12, 12/12 and 16/16 in the 2—week, 2—
month, and 6—month intervals), as well as the animals euthanized in extremis or found
dead in both low and high dose groups. The most common locations of the pigmented
cells were the subretinal space and the vitreous body as confirmed by immunostaining
of human cell— and RPE—specific kers. In the subretinal space, pigmented cells
tended to be restricted to the injection site at the earlier time points, whereas at the later
time points they were present at locations distant from the injection sites, suggesting
local cell spreading. There was a slight increase in average total number of pigmented
cells per eye at the h time point compared to 2—week or 2—month time points in
males. This sed number of pigmented cells of human origin was supported by the
qPCR analysis.
Long—term engraftment of the RPE cells is illustrated in Figure 27A. ted
cells stain ve for Human Nuclei and PMEL17 in NOD-SCID subretinal space 9
months post transplant.
Figure 27B is a photograph illustrating the clustered at the place bleb following
injection. Figure 27C is a photograph illustrating the subsequent spreading of the cells
into a monolayer following ion.
RPE was not associated with any organ weight changes. There were no
macroscopic and microscopic changes in the untreated right eyes and the non—eye
organs examined in this study which included brain, heart, kidneys, liver, lung,
mandibular lymph nodes, spinal cord, spleen, and thymus. uman nuclei
ker antibody stain (Human Nuclei) was observed in 64%, 36%, and 73% of the
tested left eyes at 2—week, h, and 6—month time points, respectively, in the
animals examined in the high dose group.
The highest detection level for Human Nuclei was noted in pigmented cell
populations within the subretinal space followed by the vitreous body. Anti—human
RPE—specific biomarker PMEL17 staining was observed in most of the s tested
s another RPE—specific biomarker, RPE65, had various levels of detection at the
different time points. These RPE—specific biomarkers were mostly detected in the
subretinal space and less in the vitreous body. Human cell proliferation biomarker Ki67
was detected in only a few cells in a small number of animals, mainly in ted
cells within the vitreous body and less within the subretinal space. The incidence of
Ki67 positivity decreased over time with only one animal at 6 month. The Ki67—positive
cells were not associated with any abnormal morphology.
Several microscopic changes were noted at the injection site across all the time
points and all the study groups and considered related to the surgical injection
procedure. Some of these changes were slightly more prominent in s examined in
the high dose group at 6 months. For example, retinal detachment was noted in one
animal and the incidence or ty of retinal degeneration/atrophy or fibroplasia was
slightly increased compared to the vehicle control group.
There were no RPE—dependent effects on animal mortality rate and survival.
Conclusion
No local or systemic toxicologic, lethal, or tumorigenic effects were observed in
the NOD/SCID animal model during the 6—month study period following single
injection of RPE at dose levels of up to 100,000 cells/ul/eye. Biodistribution of RPE
cells was restricted to the d left eye with local subretinal cell spreading from the
subretinal injection site as a function of time. RPE cells were present predominantly in
the subretinal space followed by the vitreous body in most of the animals examined in
the high dose group at 2—week, 2—month, and 6—month intervals, with variable vity
in staining by antibodies against the human nuclei and/or human RPE—specific
biomarkers. The persistence of RPE cells in the eye was ted to be at least 6
months with very limited cell proliferation. The limited proliferation took place mostly
in the vitreous body and had no adverse effects. There was evidence that the number of
RPE cells increased in the treated eye over time, although this was accompanied by
decreased proliferation incidence in the inal population examined. Expression of
both RPE specific s RPE65 and PMEL17 was predominantly in RPE cells within
the subretinal space as opposed to those within the us body, where most of Ki67—
positive cell nces were found. The latter suggests that the increase in RPE cells
over time is limited to the vitreous space and that the expression of specific RPE65 and
PMEL17 RPE markers may be regulated by the microenvironment. In conclusion, based
on the data presented above, there are no serious safety concerns d to the injection
of the presently described RPE cells as compared to vehicle control group.
EXAMPLE 8
Expression 0fPax-6 in the RPE cells
Objective: Development of a FACS based method for assessing the level of
PAX—6 in human retinal pigment epithelial (RPE) cells.
MATERIALS AND METHODS
Frozen RPE cells (generated as described in Example 4, were thawed spun
down, re—suspended in 1 ml PBS minus, filtered through a 35pM cell strainer and
counted with the NC—2OO cell counter. The cell concentration was adjusted to ~lx106
cells/ml in PBS minus. 1 ill/ml FVS450 was added to each ml cell sion followed
by vortexing and tion for 6 minutes at 37 0C. FVS450 was quenched with 0.1%
BSA(-Ig)-PBS minus, and pended in 0.1% BSA(-Ig)-Fc-block (5 min at RT) to
block all Fc—epitopes on the cells. Cells were then fixed and stained with anti—Pax—6
antibody (AF647 Cat#562249).
RESULTS
As can be seen in Figure 29, cells at P0 and P2 are positive for PAX6 (81.5%-
82.5% at PO and 91.3%—96.l% at P2). P2 is the passage at the end of the production
process and P0 is two expansion stages earlier. The data was shown to be consistent
across batches, as shown in Figures 29 and 30. In on, the present inventors showed
by FACS analysis that the RPE cells double stained for PAX—6 and CRALBP (Figure
31).
EXAMPLE 9
Identification ofproteins secreted by the RPE cells
Objective: To identify a signature of proteins (known and new) ed by the
n® (RPE cells) that can be used as a batch release potency assay as well as a
process control assay.
Supernatants were collected from RPE cells (generated as described in Example
3) that were cultured under different culture conditions indicated below. Supernatants
were then screened using the G6 and G7 RayBiotech arrays according to manufacturer’s
ctions after an overnight tion of the supematants with the related array.
1. RPE drug product cells post thawing cultured for 4 and 14 days on 12—well
plate 06 cells/well at Passage 3) (referred to herein as OpRegen®).
2. RPE drug product cells post thawing cultured for 14 days on 12-well plate and
then cultured for 3 weeks on a Transwell (as per AM—RPE—15) and demonstrated TEER
>500Q. Supernatants were taken from the apical and basal chambers.
3. Cells generated according to the protocol bed in Example 3, prior (QC3)
and post (QC4) Activin A ent.
4. Nutristem medium (Nut—) without addition of TGFB and FGF.
Supernatants were also collected from the ing cell cultures and tested by
ELISA:
l. OpRegen® drug product cells post thawing that were each cultured for 14
days on 12—well plate and then ed for 3 weeks on a Transwell (as per AM—RPE—
) and demonstrated TEER of 355Q and 5059, respectively. Supernatants were taken
from day 14 (passage 3) and from the apical and basal chambers.
2. RPE 7 cells post thawing that were cultured for 14 days on 12—well plate
(0.5x106 cells/well at Passage 3).
3. Mock VI cells at the end of Passage 1 of the production process that were
grown on 1aminin52l following Enzymatic or Mechanical isolation (as described in
Example 3). These cells were tested for potency as per AM—RPE—15 and supematants
were collected from cells at Day 14 on 12 well plate (passage 2) and cells after 3 weeks
on transwell from the apical and basal chambers.
4. Fetal HuRPE cells at Passage 3 Days 4 and 14 106 cells/well).
ELISA test validation was performed according to manufacturer’s instructions
related to each ELISA kit. In each protocol, tion with the supernatants was
overnight.
Study design: Supernatants were ted from the cells that were cultured
under different culture conditions and kept at -80°C. Following protein array analysis,
tion of the hits was measured by ELISA.
2015/051269
RESULTS
The G7 array results are provided in Table 9 herein below.
Table9
—-—-G7 Nut (-) Day4 Day14 Alical TWBasal QC3 QC4
POS 185132185132
AgRP 56 62 72 94
Axl 15 100 365 103
BTC 41 46 47 127 59
—-_—m73
Dtk 16 17 21 24
GITR-Ligand 47 52 50 56
GRO-alha 65 79 64 85
ICAM-l 13 24 27 106 56
IGFBP-6 13 172 39 167 107 66
IL-11 54 51 60 n- 64
IL-1270 15 27 19 20
2015/051269
\] 1.1
-—-—«69
IL-8 107 113 237 135 226
I-TAC 14 23 1s 24
3,736
MIP-lbeta 18 20 171,056
—-_—n15
Osteo-rote_erin 16 4,622 191 830 593
sTNFRII 13 12 13 10
1,793
TIMP—2 15 571 621 1,937 753 483 776
uPAR 68 161 67 148 276 87
546 592
VEGF-D 20 23 20 19
The G6 array results are provided in Table 10 herein below.
Table 10
W W .-
G6 14 Apical Basal QC3 QC4
POS 12,843 12,843 12,843 12,84312,843
NEG 20
Anuioenin 3,152 423 1,749 2,838 3,574
BDNF 12 nun
BLC 18 11 17
BMP—4 9 null
BMP-6 4
CK beta 8-1
CNTF
Eotaxin
E0taxin—2
E0taxin—3
FGF-6
FGF-7
Flt-3 Ligand
Fractalkjne 6 3 6
GCP-2 8 8 9
GDNF 10 11 12
GM-CSF 63 52 58
I-309 5 7 9
IFN-gamma 96 77 72
IGFBP—1 7 19 21
2 10
IGFBP—4 9 11
IGF-I 9 13
IL-10 59 59
IL- 1 3 81 77
IL-1 5 56 55 62
IL- 1 6 3 3 1
IL- 1 alpha 77 76 63 72 78
IL- 1 beta 8 12 16 12 8 n-
IL- 1ra 65 58 68 58 60
IL-2 54 53 62 51 54 190
IL-3 56 49 52 50 52 177
IL-4 7 6 7 —n-
IL-5 81 79 82 67 87 -m
IL-6 280 1,053 386 377
IL-7 64 56 62 59 63
Leptin 15 19 14 17 15
LIGHT 8 12
MCP- l 67 1,460 4,269 3,963 5,061
MCP-2 16 19 22 22 22
MCP-3 8 10
MCP-4 9 11
M-CSF 19 18
MDC 9 8
2015/051269
MIP- l -delta
MIPa1 ha
NAP-2
NT-3
PARC
PDGF-BB
RANTES
SDF-l
TARC
TGF-beta 1
TGF-beta 3
TNF-alpha
TNF-beta
RPE secreted proteins can be divided into 3 functional groups: 1) Angiogenic
ns such as VEGF and Angiogenin, 2) Extracellular matrix regulators such as
TIMP—1 and TIMP-2, and 3) Immunomodulatory proteins such as IL—6, MIF, sgpl30,
sTNF—Rl, —R3, MCP—l, and Osteoprotegerin. The or tyrosine kinase Axl
was also found to be secreted by the RPE cells. 6 ns that demonstrated high levels
of secretion and/or demonstrated a polarized secretion l/basal) pattern were
selected for validation by ELISA (angiogenin, TlMP—2, MIF, sgpl30, sTNF—Rl and
-R3). The array data also demonstrated secretion of VEGF as seen in the
polarization assay.
Angiogenin: Protein array data demonstrated increased secretion of angiogenin
along the production process (Tables 9 and 10). These results were confirmed by
ELISA demonstrating that the level of angiogenin secreted by differentiating cells that
were treated with nicotinamide prior to the addition of Activin A was 0.52 ng/mL,
whereas after the 2 weeks treatment with nicotinamide and n A, agiogenin
secretion level increased to 0.91 ng/mL (Figure 32A). RPE cells which were cultured
for 2 weeks in a 12 well plate 106 cells/well; Passage 3) post thawing secreted
angiogenin (Figure 32B). Polarized RPE cells (week 3 on transwell; TEER > 35052,
PEDF apical/basal and VEGF basal/apical ratios >1) secreted angiogenin in a polarized
manner to the basal side with low to no secretion to the apical side (basal angiogenin
levels were in the range of 01—025 ng/mL and apical angiogenin levels in the range of
0.05—0.12 ng/mL; Figure 32B). RPE 7 cells generated ing to Idelson et al., 2009
were unable to te barrier function in the transwell system (TEER below 1009)
gh could secrete VEGF and PEDF. The ability of RPE7 cells to secrete
angiogenin was tested when plated in a 12 well plate for 14 days. RPE7 secreted
angiogenin on day 14 of culture in a level that is within the range of the RPE cells
generated as bed herein (Figure 32C).
TIMP-1 and TIMP-2 Secretion: Protein array screen demonstrated secretion of
TIMP—1 and TIMP-2 from polarized and non—polarized RPE cells e 33A—E).
Interestingly, the array data showed polarized secretion of TlMP—2 to the apical side and
TIMP—l to the basal side (Figure 33A). ELISA data confirmed that TIMP—2 is secreted
mainly to the apical side by all RPE batches tested so far (Figures 33C—D apical range
of 69.9 — ll3.3 ng/mL and basal range of 11.9 — 43.7 ng/mL). TIMP—2 was also
ed by non-polarized OpRegen® cells in levels similar to the levels secreted by
normal human fetal RPE cells (HuRPE, ScienCell) (Figures 33C—E). RPE 7 cells also
secreted TIMP—2 in levels similar to the OpRegen® cells (Figures 33C-E). Interestingly,
very low levels of TIMP—2 were detected along the production process at QC3 and QC4
oints (Figure 33B).
Sgp130 Secretion by ®
0pRegen Cells: Protein array data demonstrated
increased secretion of sgpl30 along OpRegen® production process as seen in the
IPC/QC check points 3 and 4 (Tables 9 and 10). ELISA data med higher levels of
sgpl30 secretion following 2 weeks Activin A treatment C4; 1.64 ng/mL) as
compared to the levels secreted by the cells following nicotinamide treatment prior to
the addition of n A (IPC/QC3; 0.68 ng/mL) (Figure 34A). OpRegen® cells which
were cultured for 2 weeks in a 12 well plate (0.5){106 cells/well; Passage 3) post
thawing secreted sgpl30 (Figures 34B—C). RPE 7 cells cultured under similar
conditions secreted sgp130 in levels that were within the range of OpRegen® cells (1.0
ng/mL at day 14; Figure 34D). Fetal HuRPE cells secreted low sgpl30 levels both on
day 4 and on day 14.
Polarized OpRegen® cells secreted sgpl30 in a polarized manner to the apical
side with low to no secretion to the basal side (apical sgpl30 secretion levels were
n .06 ng/mL and basal sgp130 levels were in the range of 0—0.2 ng/mL;
Figures 34B—C).
Shed sTNF-RI: Very low levels of shed sTNF-Rl were detected by ELISA in
the supernatant of differentiating cells prior (IPC/QC3 0.01ng/mL) and post two weeks
treatment with nicotinamide and Activin A (IPC/QC4 0.02 ng/mL) e 35A).
OpRegen® cells which were cultured for 2 weeks in a 12 well plate 106 cells/well;
Passage 3) post thawing contained sTNF—Rl in the atant of culture day 14
(Figures 35B—C). HuRPE cells cultured under similar ions had similar levels of
sTNF—Rl in their culture supernatant while RPE 7 cells demonstrated relatively low
sTNF—Rl levels (Figure 35D).
Polarized OpRegen® cells secreted shed sTNF—Rl in higher levels to the apical
side (apical and basal sTNF—Rl levels were in the range of 0.22—1.83 ng/mL and 0.01—
0.11 ng/mL, respectively; Figures 35C—D).
sTRAIL-R3: Protein array data detected sTRAIL-R3 in the atant of
OpRegen® cells (Tables 9 and 10). ELISA confirmed the presence of sTRAIL—R3
along OpRegen® production process (493 pg/mL in QC3 and 238 pg/mL in QC4). In
fetal HuRPE culture there was no sTRAIL—R3 and in RPE 7 culture, very low levels of
sTRAIL—R3 (4 pg/mL).
Detection of MIF: Protein array data detected MIF in the supernatant of
OpRegen® cells s 9 and 10). ELISA confirmed the presence of MIF along
n® production process (100.3 ng/mL in QC3 and 44.7 ng/mL in QC4).
Polarized OpRegen® cells demonstrated higher levels of MIF in the apical side (apical
MIF levels in the range of 266—1383 ng/mL and basal in the range of 19—305 ng/mL).
EXAMPLE 10
Comparison of OpRegen® to RPE] & RPE7
Objective: To compare OpRegen® (RPE cells) with RPE cells generated
according to the protocol of Idelson et al, 2009.
MATERIALS AND METHODS
OpRegen® (RPE cells) were generated as bed in Example 3.
RPE cells were generated according to the protocol of Idelson et a1, 2009 and
named RPEl and RPE7.
WO 08239
A transwell system (as rated in Figure 28) was used to enable the
development of a polarized RPE monolayer with stable r properties and polarized
PEDF and VEGF secretion. Transepithelial electrical resistance (TEER) measurements
were used to assess the barrier function of the RPE monolayer, and Enzyme—Linked
Immunosorbent Assay (ELISA) was used to assess polarized PEDF and VEGF
secretion. Cells were thawed and cultured for 14 days in the presence of Nicotinamide.
PEDF secretion was tested on days 7 and 14. Then cells were transferred to a transwell
(Costar 3460, 0.4nm) for additional 4 weeks during which TEER was measured and
medium was collected (for assessment of cytokine ion) from the upper and lower
transwell chambers on a weekly basis up to 4 weeks. When the cells are polarized,
TEER should be above 100 Q and the ratio between the apical to basal PEDF secretion
and the basal to apical VEGF secretion should be above 1.
All OpRegen® batches that were tested demonstrated the ability to te
barrier function (TEER range of 368-688 9) and secrete PEDF and VEGF in a
polarized manner (Apical/Basal PEDF ratio ranged from 3.47—8.75 and Basal/Apical
VEGF ratio of .74) (see Table 11).
Table 11
Non-GMP
Mock
OpRegen® Clinical- OpRegen® GMP Produced RPE
Criteri
Grade Batches Research-Grade Batches Productlog According to
a for OpRegen Idelson et 21.,
release Batches
2009
RPE Purity
ELI 7+
Polarizati
on 7
TEER
at Week 3
PEDF
Apical/Ba
sal Ratio
at Week 3
informa
VEGF
tion
Basal/Api
only
cal Ratio
PEDF
secretion
day 14
ND: Not determined since TEER was below 100 S2 and big holes were seen in the culture
2015/051269
RPEl and RP7, that were produced under GMP conditions according to Idelson
et al (2009) were unable to generate barrier function (TEER < 100 Q) in 3 independent
studies. Cells seeded on the transwell were unable to generate a homogeneous closed
polygonal monolayer and big holes were seen (Figure 36). Although the cells could not
te barrier function, RPEl and RPE7 could secrete PEDF (see Table 11) and
VEGF (not shown) in levels r to OpRegen® and their level of
CRALBPJ'PMEL17+ purity was 99.91% and 96.29%, respectively, similar to n®
(Figure 37).
Based on these data, it may be concluded that RPEl and RPE7 are defective in
their ability to generate tight on.
gh the invention has been described in conjunction with specific
embodiments thereof, it is evident that many alternatives, modifications and ions
will be apparent to those skilled in the art. Accordingly, it is intended to embrace all
such alternatives, modifications and variations that fall within the spirit and broad scope
of the appended claims.
All publications, patents and patent applications mentioned in this specification
are herein incorporated in their entirety by reference into the specification, to the same
extent as if each individual publication, patent or patent application was specifically and
individually indicated to be incorporated herein by reference. In addition, citation or
identification of any reference in this application shall not be construed as an admission
that such reference is available as prior art to the present invention. To the extent that
section headings are used, they should not be construed as necessarily limiting.
Claims (46)
1. A population of human polygonal RPE cells, wherein at least 95 % of the cells thereof co—express premelanosome protein (PMEL17) and cellular retinaldehyde binding n P), wherein the trans—epithelial electrical resistance of the population of cells is greater than 100 ohms.
2. A population of human RPE cells, wherein at least 80 % of the cells f co—express premelanosome protein (PMEL17) and cellular ldehyde binding protein (CRALBP) and wherein cells of the population secrete each of angiogenin, tissue inhibitor of metalloproteinase 2 (TIMP 2), e glycoprotein 130 (sgpl30) and soluble form of the ubiquitous membrane receptor 1 for tumor necrosis factor—0t (sTNF— R1).
3. The cell population of claim 1, wherein cells of the population secrete each of angiogenin, tissue tor of metalloproteinase 2 (TIMP 2), e glycoprotein 130 0) and soluble form of the ubiquitous membrane receptor 1 for tumor necrosis factor—0c (sTNF—Rl).
4. The cell population of claims 2 or 3, wherein the cells secrete said angiogenin, said TIMP2, said sgp130 or said sTNF—Rl in a polarized manner.
5. The cell population of claims 2 or 3, wherein the cells secrete each of said angiogenin, said TIMP2, said sgpl30 and said sTNF—Rl in a polarized manner.
6. The cell population of claims 4 or 5, wherein the ratio of apical secretion of sgpl30: basal secretion of sgpl30 is greater than 1.
7. The cell population of claims 4 or 5, wherein the ratio of apical secretion of l: basal secretion of sTNF—Rl is greater than 1.
8. The cell population of claims 4 or 5, wherein the ratio of basal secretion of angiogenin: apical secretion of angiogenin is greater than 1.
9. The cell population of claims 4 or 5, wherein the ratio of apical secretion of TIMPZ: basal ion of TIMP2 is greater than 1.
10. The cell tion of claims 1 or 2, wherein the number of Oct4+TRA—1— 60+ cells in the population is below 1:250,000.
11. The cell tion of any one of claims 1—10, wherein at least 80 % of the cells express Bestrophin 1, as measured by staining.
12. The cell population of any one of claims 1—11, wherein at least 80 % of the cells express Microphthalmia—associated transcription factor {MITF), as measured by immunostaining.
13. The cell population of any one of claims 1—12, wherein more than 50 % of the cells express paired box gene 6 (FAX—6) as measured by FACS.
14. The cell population of any one of claim 1—13, wherein the cells secrete greater than 750 ng of Pigment epithelium—derived factor (PEDF) per ml per day.
15. The cell population of any one of claim 1—14, wherein the cells secrete PEDF and ar endothelial growth factor (VEGF) in a polarized manner.
16. The cell population of claim 15, wherein the ratio of apical secretion of PEDF: basal secretion of PEDF is greater than 1.
17. The cell population of claim 16, n said ratio remains greater than 1 following incubation for 8 hours at 2—8 ° C.
18. The cell population of claim 2, wherein the trans—epithelial electrical resistance of the population of cells is greater than 100 ohms.
19. The cell population of claim 1 or 18, wherein said trans—epithelial electrical resistance of the cells remains greater than 100 ohms following incubation for 8 hours at 2—8 ° C.
20. The cell population of claims 15 or 16, wherein the ratio of basal ion of VEGF: apical secretion of VEGF is greater than 1.
21. The cell population of claim 20, wherein said ratio remains greater than 1 following incubation for 8 hours at 2—8 0 C.
22. The cell tion of any one of claims 1—21, being capable of rescuing visual acuity in the RC5 rat following subretinal administration.
23. The cell tion of any one of claims 1—21, being capable of rescuing photoreceptors for at least 180 days post—subretinal administration in the RC8 rat.
24. The cell population of any one of claims 1—23, being generated by ex— Vivo entiation of human embryonic stem cells.
25. The cell population of any one of claims 1—24, being generated by: (a) culturing human embryonic stem cells in a medium comprising nicotinamide so as to te differentiating cells, wherein said medium is devoid of activin A; (b) culturing said differentiating cells in a medium comprising nicotinamide and n A to generate cells which are further differentiated towards the RPE lineage; (c) culturing said cells which are further differentiated towards the RPE lineage in a medium comprising nicotinamide, wherein said medium is devoid of activin
26. The cell population of claim 25. wherein said embryonic: stem. cells, are propagated in a medium comprising bFGF and ’IGFB.
27. The cell population of claim 25, wherein said embryonic stem cells are cultured on human cord fibroblasts.
28. The cell population of claims , wherein steps (a)—(c) are effected under ions wherein the heric oxygen level is less than about 10 %.
29. The cell population of claim 28, wherein the method further comprises culturing said differentiated cells in a medium under conditions wherein the atmospheric oxygen level is greater than about 10 % in the presence of nicotinamide ing step (c).
30. A pharmaceutical composition comprising the cell population of any one of claims 1—29, as the active agent and a pharmaceutically acceptable carrier.
31. Use of the cell population of any one of claims 1—30, for treating a retinal degeneration.
32. A method of generating RPE cells comprising: (a) culturing otent stem cells in a medium comprising a entiating agent so as to generate differentiating cells, wherein said medium is devoid of a member of the transforming growth factor B (TGF [3) superfamily; (b) culturing said differentiating cells in a medium comprising said member of the transforming growth factor B (TGF [3) superfamily and said differentiating agent to generate cells which are r differentiated towards the RPE lineage; (c) culturing said cells which are further differentiated towards the RPE lineage in a medium comprising a differentiating agent so as to generate RPE cells, wherein said medium is devoid of a member of the transforming growth factor B (TGF [3) superfamily, n steps (a)-(c) are effected under conditions wherein the atmospheric oxygen level is less than about 10 %.
33. The method of claim 32, wherein step (a) is effected under non—adherent conditions.
34. The method of claim 33, wherein said non—adherent conditions comprise a non—adherent culture plate.
35. The method of claim 32, wherein step (a) comprises: i) culturing said cultured population of human otent stem cells in a medium comprising nicotinamide, in the absence of activin A; under non—adherent conditions to generate a r of cells comprising differentiating cells; and subsequently ii) culturing said differentiating cells of (i) in a medium comprising nicotinamide, in the absence of activin A under adherent conditions.
36. The method of claim 35, further comprising dissociating said cluster of cells prior to step (ii) to generate clumps of cells or a single cell suspension of cells.
37. The method of claim 32, further comprising culturing said differentiated cells in a medium under conditions wherein the atmospheric oxygen level is greater than about 10 % in the presence of a entiating agent following step (c).
38. The method of claim 32, wherein said member of the transforming growth factor B (TGF B) superfamily is selected from the group consisting of TGFBl, TGFB3 and activin A.
39. The method of claim 32, wherein said differentiating agent of step (a) and said differentiating agent of step (c) are identical.
40. The method of claim 32, wherein said differentiating agent of step (a) is namide (NA) or 3— aminobenzamide.
41. The method of claim 32, further comprising selecting polygonal cells following step (c).
42. The method of claim 41, further comprising propagating said polygonal cells.
43. The method of claim 42, n said propagating is effected on an adherent surface.
44-. The method of claim 32, n said pluripotent stem cells comprise. embryonic stem cells.
45. The method of Claim 44, wherein said embryonic stem cells are propagated in a medium comprising bFGF and, TGFB.
46. The method of claim 44, wherein said embryonic stem cells are cultured on human cord fibroblasts.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/097,753 | 2014-12-30 | ||
US62/116,972 | 2015-02-17 | ||
US62/195,309 | 2015-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ733006A true NZ733006A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220169982A1 (en) | Rpe cell populations and methods of generating same | |
US20230028133A1 (en) | Methods of treating retinal diseases | |
US20230051803A1 (en) | Assessing retinal pigment epithelial cell populations | |
NZ733006A (en) | Rpe cell populations and methods of generating same |